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Abstract 
N-acylethanolamides (NAE) are involved in a variety of biological processes ranging from fat 
oxidation to inflammation mediation. Recently, the HRASLS family, a group of class II tumour 
suppressor proteins, have been identified and shown to have in vitro phospholipase as well as N-
acyltransferase activity. HRASLS-1 functions predominantly as an N-acyltransferase to generate 
NAPE in animal cells that can be further metabolized into bioactive NAEs.  Although this enzyme 
has been characterized with regards to its molecular function, no physiological role has been 
identified. In order to gain some insight into possible cellular or tissue functions for this enzyme, 
studies were conducted to analyze Hrasls-1 gene expression under changing nutritional states, 
during inflammation, and at different embryonic developmental time points. Two distinct Hrasls-
1 transcripts that code for the same protein, a 0.8 kb and a 2.9 kb variant., were initially 
identified. Stability of the transcripts was tested by treating cultured BV2 microglial 
immunocytes with actinomycin D to arrest transcription, followed by qPCR analysis of Hrasls-1 
mRNA levels. It was found that the Hrasls-1 0.8kb transcript variant has a shorter half-life than 
the 2.9 kb variant. Next, expression of the Hrasls-1 transcript variants was analyzed within mice 
that were non-fasted, fasted or re-fed. Hrasls-1 expression was determined in liver, kidney, white 
adipose tissue, heart, and brain. In the liver, kidney and white adipose, Hrasls-1 was induced by 
fasting, while in the heart and brain there was no significant induction during any of the different 
nutritional states. This work suggests a possible role for HRASLS-1 in regulation of the substrate 
oxidation between fasting and re-feeding. The regulation of Hrasls-1 and the generation of NAPE 
upon induction of inflammation in BV2 microglial immunocyteswas testes. Hrasls-1 total levels 
were induced 24 h after activation of BV2 cells with lipopolysaccharide (LPS), and this was 
largely due to an increase in the 0.8 kb transcript variant. In line with these findings, there was an 
increase in the incorporation of [14C]palmitate into NAPE. Whole embryos were analyzed at 
 iv 
different developmental stages (E10.5, 14.5 and 18.5), in order to characterize the regulation of 
Hrasls-1 in embryogenesis. It was found that the 2.9kb transcript variant showed significant 
modulation of expression throughout the measured time points. These results show regulation of 
Hrasls-1 gene expression under differing nutritional, developmental and inflammatory 
conditions, and are consistent with a role for modulation of NAPE synthesis in conditions where 
NAEs play a signaling role.  
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Chapter 1 
Introduction 
N –acylethanolamides  (NAEs) are “ethanolamides of long chain fatty acids” 1 that are 
naturally occurring biological signalling molecules and endogenous lipid mediators in various 
organisms including animals and plants21, 94. NAEs are synthesized from precursor N-
acylphosphatidylethanolamides (NAPEs). Depending on the acyl chain present on the NAE, which 
in turn is dependant on the fatty acyl chain found on the NAPE precursor, the NAE species 
generated may have a variety of physiological functions as well as a unique affinity to bind and 
activate specific receptors 97. The most abundant NAEs found in animal tissue include N-
palmitoylethanolamide (PEA), N-oleoylethanolamide (OEA), and N-steroylethanolamide 
(SEA)26,98. These lipid molecules influence a variety of physiological functions, ranging from anti-
inflammatory and neuroprotective responses107, 108  toanorexiant roles that regulate feeding and 
body weight116,117. Understanding the regulation of NAPEs/NAEs is therefore important for 
understanding normal physiology, and has implications for treating myriad disease conditions 
from obesity to cancer, diabetes, and heart disease.  
NAEs are synthesized fromglycerophospholipids via a “two-step enzymatic pathway”23, 24. The 
first reaction transfers a fatty acyl chain from a donor glycerophospholipid to the amino group of 
an ethanolamine phospholipid25, catalyzed by an N-acyltransferase enzyme2,3,25.A family of class 
II tumour suppressor proteins has been identified and characterized with this activity 4. This 
family is known as the Harvey-Ras-like tumour suppressor enzymes (HRASLS), and consists of 
five similarly structured enzymes (HRASLS-1-5)37-39. Limited molecular analysis of HRASLS-1 has 
identified it as having relatively high N-acylation activity, both in vitro and in vivo5. This suggests 
that HRASLS-1 may play a role in the regulation of some physiological and disease processes, by 
modulating the in vivo generation of NAPE molecules and their downstream signaling products, 
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NAEs. However, a role for HRASLS-1 in normal or aberrant physiology has not yet been 
investigated. Identifying conditions under which Hrasls-1 expression is modulated will provide 
insight into possible sites of action and physiological roles for this enzyme. Therefore, the 
primary goal of this work was to assess the expression of Hrasls-1 under changing physiological 
conditions known to be regulated, at least in part, by NAE signaling activity. Studies in this thesis 
were centered on the expression of Hrasls-1 in inflammation, embryological development, and 
changes in different dietary states. 
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Chapter 2 
Biochemical Foundations 
2.1 Overview of N-acylphosphatidylethanolamide synthesis 
The HRASLS-1 pathway directly synthesizes NAPEs. Understanding the regulation of 
HRASLS-1 is therefore important for understanding the regulation of NAE signaling, and the 
physiological and disease processes that are controlled by NAE-regulated pathways.  
NAEs are bioactive molecules generated in response to a variety of stimuli 6. They tend to 
be rapidly produced and then rapidly hydrolyzed, and therefore are short-lived signaling 
intermediates, making the amount and chemical composition of precursor NAPEs an important 
regulatory element in NAE biosynthesis and action. In the classical “N-acylation/phospholipase 
D” (NAPE-PLD) pathway7,the first stepforms a NAPE, by the transfer of the sn-1 fatty acyl chain 
from a donor glycerophospholipid to the primary amino group of an ethanolamine phospholipid 
such as PE 8 (Figure 1).   A wide variety of fatty acyl species can be attached to the nitrogen of 
phosphatidylethanolamine, and the availability of different fatty acids at the sn-1 position of 
donor glycerophospholipids is an important determinant of the specific NAPE species that are 
produced in any given tissue 9. In the second step of NAE synthesis, phospholipase D-mediated 
cleavage releases an NAE, leaving phosphatidic acid. Given the role of NAEs in signaling events, 
the initial step of NAPE biosynthesis has considerable biological relevance, since the specific 
nature of the acyl species attached to the ethanolamine group will determine the corresponding 
NAE that can be synthesized in the second enzymatic step, and hence the specific biological 
signaling role that it can play3. In mammalian cells, two groups of NATs – calcium-dependent NAT 
(Ca-NAT) and calcium independent NAT (iNATs) - are responsible for the synthesis of NAPEs, 
and both utilize glycerophospholipids as acyl donors. HRASLS-1 belongs to the second group, the 
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iNATs, which were discovered after Ca-NAT. An acyl-CoA dependent N-acyltransferase called 
NAPE synthase has also been identified, but is found only in plants. 
 
2.2 Ca-dependent NAT activity, expression and signaling role 
Ca-NAT activity has been studied in various animal tissues3. All information on this 
enzyme is based on studies of activity, since it has not yet been identified and cloned. As a result, 
it is unknown whether Ca-NAT activity in cells is a result of one enzyme or a group of enzymes, 
and it is not possible to determine mRNA expression regulation of Ca-NAT(s) with changing 
physiological conditions. Activity assays have found this enzyme to be catalytically active at 
neutral and alkaline pH 10,11. Cellular Ca-NAT activity results in the formation of NAPE using 
phospholipids as acyl donors, with release of an acyl chain occurring entirely from the sn-1, and 
not the positionsn-2 position3. Ca-NAT activity is significantly activated by Ca2+ 3. Phospholipids 
that act as acyl donors for Ca-NAT activity include phosphatidylcholine (PC), 1-acyl-lyso PC, PE 
and cardiolipin3. The fatty acyl-chain acceptors include phospholipids such as PEs, alkyl acyl-
type, and alkenyl-acyl type PEs, as well as lyso PE 3. Ca-NAT does not show preference for a 
specific length or unsaturation of the acyl chain chosen for transfer 10.  
Inflammation is associated with calcium release from tissues and immunocytes. 
Accumulation of NAPE and NAE have been found in inflammation and cellular degeneration12. 
NAPE and NAE generation has been associated with the activation of the Ca-NAT enxymeby 
Ca2+stimulation3.  Whether calcium-independent N-acyltransferases, such as HRASLS1, could also 
be activated by inflammation alongside Ca-NAT(s) has not been tested.  
Similar to HRASLS-1 expression patterns, the highest activity for Ca-NAT activity in 
rat,was found in brain, with lower levels in testis and muscle13-15. The highest activity in brain 
was observed in the brainstem, with intermediate activity in the cortex, striatum, hippocampus, 
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medulla, and cerebellum, and the lowest activity in thalamus, hypothalamus, and olfactory 
bulbs13-15.  Taken together, these data suggest that NAPE synthesis is critical in brain signalling, 
and that both Ca-NATs and iNATs may play important roles in mediating these processes. 
 
2.3 NAPE Synthase N-acylation Activity and Acyl Donor Specificity 
In addition to the mammalian acyltransferases, the enzyme NAPE synthase has been 
cloned from the plant Arabidopsis thaliana16. The enzyme is of 284 amino acids long, and is 
characteristically similar toglycerophospholipidacyltransferases such as lyso PC acyltransferase3. 
Like Ca-NAT, NAPE synthase catalyzes the N-acylation of PE, although it uses acyl-CoA instead of 
glycerophospholipid as an acyl donor3. Since purified recombinant NAPE synthase uses only 
activated acyl-CoA, but not free fatty acids, this rules out the possibility that it incorporates free 
fatty acid directly into PE 3. Currently, it is not known which enzymes would be responsible for 
this catalysis within animal tissues3.  
 
2.4 Identification of iNAT Family Members, Catalytic Activity and Enzymatic Role 
iNATs were initially enzymatically characterized for a conserved motif, shared with  
lecithin retinol acyltransferase (LRAT). This motif contains a reactive cysteine residue involved in 
the family’s catalytic activity16,17. LRAT catalyzes the transfer of a palmitoyl chain from the sn-1 
position of phosphatidyl choline to all-trans-retinol, formingretinyl ester18. LRAT has also shown 
activity in acylating the amino group of retinylamine19. This catalyticresemblance between LRAT 
and Ca-NAT encouraged the examination of LRAT-homologous proteins for similar PE N-
acylation activity3. 
The Harvey-Ras-like tumor suppressor (HRASLS) enzymes consist of five, similarly 
structured class II tumor suppressor proteins (HRASLSL1-5) 20-22 that make up the iNATenzymes. 
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While all five proteins are encoded in the human genome, murine studies have only identified the 
presence of HRASLS-1, HRASLS-3, and HRASLS-523. HRASLS-1-4 range from 162 to 168 amino 
acids, with a molecular weight of ~18 kDa4. HRASLS-5 has 279 amino acids and is larger than the 
others, at ~31 kDa in size4. In mice, HRASLS-1 is located on chromosome 16, while HRASLS-3 and 
-5 are located on chromosome 194. 
All five members of the HRASLS family have been shown to have in vitro phospholipase 
A1/2 (PLA1/2) activity, which releases a fatty acid from the sn-1 or sn-2 position of a 
glycerophospholipid. All five members have also been shown to have in vitro O-acyltransferase 
activity, catalyzing the transfer of an acyl group from a glycerophospholipid donor to the 
hydroxyl group of a lysophospholipid, as well as in vitro N-acyltransferase activity, catalyzing the 
formation of NAPE 5,24-26.  In vivo, however, these enzymes do not always recapitulate their in 
vitro functions, tending to favor only one of these specific catalytic functions. When considering 
the iNATs, it is important to note that their catalytic properties differ from those of the Ca-NAT 
enzyme in several ways, most predominantly by the fact that the activity of these proteins is only 
marginally increased by Ca2+ addition, indicating Ca2+-independent activity10.  
Despite the conservation of their catalytic sites, the HRASLS proteins show distinctive 
tissue specificity and unique catalytic preference for different reactions. 
 
2.4.1 HRASLS-1 
HRASLS-1 was “originally cloned by differential display between two mouse cell lines, the 
embryonic fibroblast line C3H10T1/2, and the chondrogenic ATDC5 line” 27.HRASLS-1 is highly 
expressed in mouse heart, brain and testis 28-30. HRASLS-1 shows predominant PLA1 activity over 
PLA2 activity, as well as a preference for O-acylation of the sn-1 position of lyso PC 5. Relative to 
other HRASLS family members, HRASLS-1 shows in vitro PE N-acylation activity that is as high as 
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murine/human HRASLS-5 and human HRASLS-25. However, it is clear that in vivo HRASLS-1 
functions predominantly as an N-acyltransferase to generate NAPE in animal cells, which can be 
further metabolized into bioactive NAEs5,31.  
 
2.4.2 HRASLS-2 
Purified recombinant human HRASLS-2 shows the highest in vitro acyltransferase activity 
among the HRASLS family members31, with higher PE N-acyltransferase and lysophospholipid O-
acyltransferase activities than either HRASLS-3 or HRASLS-426. Constitutive expression of 
HRASLS-2 in stably transfected human embryonic kidney 293 cells (HEK 293) increases 
endogenous levels of NAPE and NAE31, indicating that HRASLS-2 acts as a NAPE-forming acyl-
transferase in vivo, and the enzyme activity of HRASLS-2 has been found to increase production 
of downstream NAE containing 16:0, 18:0, and 18:132. However, unlike HRASLS-1, HRASLS-2 
shows a different tissue expression profile, with highest levels in the small intestine, kidney and 
trachea 4.  Additionally, HRASLS-2 is absent from the murine genome, and therefore unlike 
HRASLS-1, cannot regulate NAPE/NAE-mediated pathways in mouse cells or tissues 23. 
 
2.4.3 HRASLS- 3 
HRASLS-3 was the first HRASLS family member to be characterized enzymatically33. In 
vitro, a weak PE N-acyltransferase activity was detected34, although cells overexpressing 
HRASLS-3 do not show a significant increase in NAPE synthesis in vivo23. Rather, recombinant 
murine and human HRASLS-3 show a PLA1/2-like hydrolyzing activity toward various PCs and 
PEs25,33. As a result, HRASLS-3 is best considered a PLA rather than an iNAT, despite homology 
with the HRASLS family, and likely does not modulate the same pathways as HRASLS-1. 
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2.4.4 HRASLS-4 
HRASLS-4 has in vitro enzymatic activity that is similar to HRASLS-3, with significant 
PLA1/2 activity and relatively low PE N-acylation activity26,35. In contrast, however, transient 
expression of the protein caused intracellular accumulation of NAPE, indicating that N-
acyltransferase activity predominates over PLA activity of HRASLS-4 in vivo23. However, unlike 
HRASLS-1, HRASLS-4 is primarily expressed in skin, colon, lung and liver tissues36-39 and, 
furthermore, HRASLS-4 is one of two HRASLS family members found in humans but not mice 23, 
where my studies were conducted. 
 
2.4.5 HRASLS-5 
HRASLS-5 shares a high degree of homology with both HRASLS-1 and HRASLS-340, and 
has shown conservation through human, mouse and rat species24. Unlike other HRASLS family 
members, this enzyme is detected primarily in the cytosol, instead of the membrane region of 
cells24. Enzymatically, HRASLS-5 has N-acyltransferase activity and is able to abstract an acyl 
group from not only the sn-1 position, but also the sn-2 position of PC24. Although HRASLS-5 is 
most likely to play a similar role to HRASLS-1 in mouse tissues and cells, the tissue distribution of 
this enzyme is different, with HRASLS-5 showing predominant expression in the pancreas 40.  
 
2.5 NAE Synthesis via NAPE-PLD-Dependent and Independent Pathways 
 As previously mentioned, the second enzymatic reaction involves the hydrolysis of NAPE 
to NAE by NAPE-hydrolyzing phospholipase D (NAPE-PLD) 41. Recombinant NAPE-PLD 
producesseveral long-chain NAEs3, including N-arachidonoylethanolamine (AEA), PEA and 
OEAfrom corresponding NAPEs41. NAPEs with medium-chain N-acyl species (C4:0 and longer) 
have also been shown to be active substrates, while N-acetyl-PE ad N-formyl-PE are much less 
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active substrates for NAPE-PLD42. Ca2+stimulation has shown to have a very minimal effect on 
membrane-associated NAPE-PLD 3.  
Alternatively, recent evidence has identified NAPE-PLD independent pathways for NAE 
formation 3. N-acyl-lyso PE (Lyso NAPE), glycerophospho(N-acyl)ethanolamine (GP-NAE), and 
NAE phosphate can all act as “intermediate metabolites” in these unique NAE-synthesizing 
pathways43(Figure 1). Considerable additional work will be required to clearly understand the 
role of HRASLS-1 and other NAPE/NAE pathway enzymes in NAE biosynthesis. 
 
2.6 NAE Degradation Pathways and a Possible Mechanism for Elevating Levels of NAE 
Degradation of NAE is achieved by hydrolysis of the molecule to a fatty acid and an 
ethanolamine. Fatty acid amide hydrolase (FAAH) is the most common enzyme used to employ 
this degrdation44(Figure 1). FAAH is broadlyspread through mammalian organs, and  hashigh 
sensitivity to serine hydrolase inhibitors45. Anandamide is the most reactive substrate for FAAH, 
and PEA is the least45.  In addition to FAAH, another “NAE-hydrolyzing amidohydrolase” exists46. 
N-acylethanolamine-hydrolyzing acid amidase (NAAA) differs from FAAH by its preference for 
PEA to other NAEs, and the ability of some ester and amide compounds to inhibit NAAA activity 
without having any inhibitory effects on FAAH46,47. Thus, although N-acyltransferases such as 
HRASLS-1 primarily control the species of NAE that are synthesized in cells through regulation of 
the synthesis of precursor NAPEs, the substrate selectivity of the NAE-hydrolyzing enzymes may 
also contribute another level of regulatory control to the concentrations of specific NAEs found in 
cells. Understanding of the regulation of enzymes in both of these pathways will therefore be 
required to fully understand NAE regulation in cells. 
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Figure 1. Major biosynthetic and degradative pathways of NAPE. PC is a representative acyl 
donor phospholipid. Abh4, α/β-hydrolase 4; GDE1, glycerophosphodiesterase 1; PA, phosphatidic 
acid; SHIP1, Src homology 2 domain-containing inositol-5-phosphatase 143. 
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2.7 NAE-Activated Signaling Pathways 
 NAEs are potent signalling molecules, involved in a host of biological processes. Important 
in regulating the biological activity of NAEs is the presence and nature of the signaling mediators 
through which these signalling lipids act. These include cell surface receptors, G-protein coupled 
receptors, and transcription factors.  Specifically, peroxisome proliferator-activated receptor 
alpha (PPAR), transient receptor potential cation channel subfamily V member 1 (TRPV1), and 
G-protein coupled  receptor 119 (GRP119) have shown activation by NAEs. I will discuss each 
receptor individually, in order to offer a better understanding of the possible cellular and 
physiological effects that HRASLS-1 may mediate through control of NAPE/NAE biosynthesis.  
 
2.7.1 PPAR- activation by NAEsCan Regulate Substrate Oxidation, Inflammation and 
Embryogenesis  
Peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription 
factors48.They control gene expression by binding to retinoid x receptor (RXR) to specific DNA 
sequence elements termed peroxisome proliferator response elements (PPRE) 48. In following, 
this complex binds to related sequences in promoter regions of target genes, many involved in 
the catabolism of fatty acids 49. There are three main isotypes of PPARs: PPAR-, PPAR-, and 
PPAR-.  Once PPARs are activated, they bind to DNA and regulate gene transcription. They are 
distinctive by individual patterns of expression, and also by their ligands ability toactivate each 
receptor 50.   
The “multifunctional ligand-binding pocket of PPAR-α allows this protein to recognize 3 
distinct classes of natural agonists:” 51NEFAs, oxygenated fatty acids, and NAEs such as PEA and 
OEA51. The presence of a role for NAEs in regulation of PPAR-α, therefore also suggests a role for 
their upstream regulators - the N-acyltransferases like HRASLS-1, in regulating PPAR-α and its 
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various functions. This includes mediating the switch to increased -oxidation in fasting. PPAR-
αis highly expressed in tissues with high rates of mitochondrial fatty acid oxidation52, such as 
liver, heart, muscle, kidney, brain 53. PPAR-regulates the expression of genes involved in the 
peroxisomal and mitochondrial -oxidation pathways, such as acyl-Coenzyme A oxidase 1 
(Acox1), the first enzyme of the fatty acid -oxidation pathway54, as well as 
carnitinepalmitoyltransferase 1(CPT1), an enzyme that is essential for the-oxidation of longer 
fatty acids55. PPAR-αalso regulates fatty acid transport protein (FATP), fatty acid translocase 
(FAT/CD36), liver cytosolic fatty-acid binding protein (L-FABP), and uncoupling proteins 2 and 3 
(UCP2 and UCP3) 56. By altering the transcription of these genes, activated PPAR-α,can increase 
hydrolysis of TAG and oxidation of fatty acids, and increase cellular fatty acid uptake57  - effects 
that are all activated with fasting. Investigation of ligands activating PPAR-α-mediated fat 
metabolism is necessary to gain greater insight into mechanisms responsible for substrate 
oxidation regulation. Analysis of the expression of genes that are regulated by PPAR-αprovides a 
surrogate measure of PPAR-αactivation. 
PPAR-α can regulate the development of inflammation by inhibition of proinflammatory 
transcription factors NF-κB and AP158.Negative regulation of acute inflammation by PPAR-α has 
been confirmed in PPAR-α-deficient mice seem, which more sensitive to inflammatory stimuli 59. 
Since NAEs such as palmitoylethanolamide (PEA) have been found to have anti-inflammatory 
effects, it is also possible that N-acyltransferases such as HRASLS-1 may be involved in 
inflammation resolution, also through activation of the NAPE/NAE/ PPAR-signalling pathway. 
To date this has not yet been studied.  
Finally, PPAR-α is differentially expressed during embryonic development. Reports of the 
expression of PPAR-α indicate detection of mRNA primarily only in later stages of 
development60,61. Northern blot analysis of total RNA from homogenized whole mouse embryos 
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failed to detect PPAR-α from E9.5 to E12.5, which was followed by weak mRNA expression on 
E13.5 that increased from E14.5 through E18.561. Thus, the expression of PPAR-α is expected to 
play a critical role in mediating developmental signaling events during later stages of gestation, 
and may influence the responses of an embryo to PPAR-α agonists including NAEs. The 
expression of NAEs within embryogenesis has gained very little attention, and even less for the 
enzymes responsible for their synthesis.  
 
2.7.2 TRPV1 Activation by OEA and AEA Weakens Inflammatory Response  
The transient receptor potential (TRP) family is a family of ion channels that can “act as 
molecular transducers to depolarize neurons” 62that can set off impulses within pain 
pathways63,64. Among these ion channels, are the members of the transient receptor potential 
(TRP) family. TRPV1 receptor has gained the most attention due to its unique ability to be 
activated by capsaicin65.  Activation of TRPV1 allows for the activation of many signalling 
pathways, including those of the inflammatory response66. TRPV1 activation is “dynamic”, 
meaning that through prolonged or consistent activation via agonist agents, such as anandamide 
(AEA) and OEA66, 67, therefractoriness of the TRPV1-expressing nerve fibers can be desensitized. 
Consequentially, this will weaken the inflammatory response observed67. Thus, N-
acyltransferases such as HRASLS-1 may also regulate inflammation resolution through the 
NAPE/NAE/TRPV1 pathway. 
 
2.7.3 GPR119 is Activated by NAEs to Enhance Nutrient Absorption  
Gut hormones such as glucose-dependent insulinotropic polypeptide (GIP), peptide YY 
(PYY), and glucagon-like peptide-1 (GLP-1), are peptides activated with the income of nutrients68. 
They regulate glucose and lipid metabolism by regulating insulin and glucagon secretion, 
 14 
accordingly69,70. GPR119 can secrete both GLP-1 and GIP71, thus GPR119 agonists control glucose 
levels by augmenting insulin secretion in pancreatic -cells and by stimulating the secretion of 
gut hormones72,73. In turn, these hormones can promote further insulin secretion and improve 
overall glucose metabolism 72,73.  NAEs are effective agonists of GPR119, specifically OEA and 
PEA68. Since GPR119-mediated events are typically activated during a nutrient replete, or fed 
state, evidence that Hrasls-1 gene expression is induced postprandially, would provide 
preliminary evidence suggesting a role for this enzyme in regulation of satiety and insulin 
responsiveness. Unfortunately, this data has not yet been examined.  
 It is important to recall that the relationship between HRASLS-1 and the discussed 
receptors is not direct. The HRASLS-1 pathway must synthesize the precursor NAPE molecules, 
in order to generate the lipid mediator NAEs. Thus, in the following section I will introduce the 
NAE molecules most relevant to the HRASLS-1 pathway, along with their individual physiological 
relevance.  
 
2.8 Physiological SignallingActivities of Anandamide and the HRASLS-1- Relevant NAEs 
NAEs are part of a group known as endocannabinoid-like compounds that share common 
biosynthetic and degradation pathways with endocannabinoids, but lack cannabinoid receptor 
affinity 74,75.  PEA, OEA, and N- stearoylethanolamide (SEA) are quantitatively major NAE’s in 
animal tissue, where they actively undergo biosynthesis and breakdown9,76. 
 
2.8.1 AEA is a Multifunctional Signalling Molecule, Although Not Likely a Major 
Downstream Product of the HRASLS-1 Pathway 
N-arachidonylethanolamide, also known as anandamide, is an “endogenous cannabinoid 
neurotransmitter” 77. Anandamide’s effects can either be mediated centrally in the brain, or 
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peripherally, and are transduced primarily by CB1 cannabinoid receptors, although it can also be 
a ligand for CB278 and TRPV179. Cannabinoid receptors were originally discovered for their 
sensitivity to -tetrahydrocannabinol, which is the primary  cannabinoid found in cannabis80. 
AEA affects multiple physiological processes, having distinct effects on the immune system by 
employing an anti-inflammatory response during increased inflammation81. Anandamide is 
important  in pre-implantation of theembryo, specifically, the development of the blastocyte from 
a 2-cell embryo82.  Anandamidealso plays a role in the regulation of feeding behavior  mainly by 
increasing food intake81. Thus, AEA may play a role in mediating each of the physiological 
processes investigated in this thesis. However, this NAE is unlikely to be a primary mediator of 
any pathway controlled by HRASLS-1/NAPE/NAE signaling, since arachidonic acid is typically 
located in the sn-2 position of glycerophospholipids, and HRASLS-1 predominantly utilizes donor 
fatty acids in the sn-1 position of glycerophospholipids. Additionally, although anandamide has 
gained the most attention as an NAE signaling molecule, it is much less abundant in animal 
tissues, accounting for less than 5% of total NAEs 83,84, and therefore suggesting that other NAEs 
likely play roles in HRASLS-1 mediated effects. 
 
2.8.2 The Anti-inflammatory Role of PEA and Related Mechanisms 
PEA is an “endogenous fatty acid amide”, acting as an anti-inflammatory protein sine the 
1950’s85.  Today, AEA is known to be “an important analgesic, anti-inflammatory and 
neuroprotective mediator”86. PEA has been proposed to act “on demand” as an anti-inflammatory 
mediator86. Unfortunately, due to the lack resources able to deliberately alter the tissue levels of 
PEA specifically, the protective functions of endogenous PEA have not yet been discerned86 
Presently, three mechanisms explain the anti-inflammatory effects of PEA. The first 
proposes that PEA acts by locally “down-regulating mast-cell degranulation” 87. The second, the 
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“entourage effect” 88 proposes that PEA is able to inhibit the degradation of AEA, and enhance its 
anti-inflammatory properties89-91. The final mechanism, the “receptor mechanism”92suggests PEA 
directly stimulates an unknown cannabinoid CB2 receptor-like target92, or the nuclear hormone 
receptor PPAR-53. PEA may eventually lead to a new therapeutic approach for the treatment of 
pathological conditions, most attractively, those associated with pain and inflammation.  
 
2.8.3 OEA Can Have Opposing Roles During Different Feeding States 
OEA is an anorexiant that controls feeding and body weight by prolonging the latency 
period between meals 93,94. As OEA was initially characterized as a primary ligand for PPAR-α, it 
suggested that OEA stimulates satiety and reduces bodyweight gain through PPAR-α activation93. 
It was also suggested that through the activation of PPAR-α, OEA lowered lipid levels in liver and 
blood93, implicating OEA with anti-obesity outcomes, such as increased lipid oxidation93.  
Further to this, the anorexic actions of OEA were hypothesized to be facilitated by 
stimulation of vagal sensory nerves95. OEA is reported to be an agonist of TRPV195 that caused 
reduced food intake in wild-type, but not in TRPV1-/- mice96. Although it has not yet been 
examined, OEA may also be regulating other metabolic responses involving TRPV1, such as 
reduction in weight gain, adiposity and triglycerides.  
In addition to actions mediated through TRPV1, OEA may also stimulate GLP-1 secretion 
from the intestinal L-cells through GPR119 stimulation97.  Administration of OEA into the 
intestinal lumen in rats,increased bioactive GLP-1 levels, supporting a role for OEA as a GLP-1 
producer in vivo97.
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2.8.4 SEA Regulates Feeding as well as Inflammation  
Very little is known about the physiological significance of SEA. SEA has been shown to 
decrease food intake with an associated decrease in liverstearoyl-CoA desaturase-1 (SCD-1) 
mRNA expression98. SCD-1 is “the rate-limiting enzyme in the biosynthesis of monounsaturated 
fats” 98. Thus, its reduction decreases the rate of lipogenesis, and promotes fatty acid oxidation99. 
Although this appears to suggest possible involvement of PPAR-, these effects have been found 
to be independent of PPAR- activation, and the pathway of SEA-mediated regulation of these 
effects has not yet been elucidated. SEA is also capable of down-regulating inflammation in 
inflamed or damaged tissue, and this effect likely involves TRPV167. 
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Chapter 3 
Rationale and Objectives 
 
3.1 Rationale 
 
 
HRASLS-1 predominantly functions as an N-acyltransferase in vivo to generate NAPEs that 
are further metabolized to bioactive NAEs31.  In contrast to the other iNATs, HRASLS-1 is the only 
murine-characterized HRASLS family member to show high N-acylation activity, and to be 
expressed in a wide variety of animal tissues 40. Evidence suggests that the type and level of NAE 
found in tissues corresponds to the type and amount of NAPE, which is determined by the 
respective donor fatty acid species available in the sn-1 position of PC in cells9. If donor PC sn-1 
fatty acid species availability primarily regulates HRASLS-1 product type, then the most 
abundant downstream products of increased HRASLS-1 activity in cultured cells are likely to be 
PEA, SEA and OEA. These NAEs have been shown to activate PPAR- or TRPV1, both of which 
may signal to regulate nutrient metabolism93, as well as mediate the inflammatory response100, 
and function in embryological development101. Regulation of these processes is critical for 
normal physiological function, and deregulation of these processes may lead to a variety of 
diseases. Understanding the regulation of NAE synthesis, therefore, is of critical importance to 
health. Enzyme mediators such as HRASLS-1 play important roles in controlling NAE 
biosynthesis.  To date, however, a role for HRASLS-1 in any physiological process has not yet 
been investigated. It is therefore likely that N-acyltransferases, such as HRASLS-1, that help to 
control NAE levels, similarly undergo changes in gene expression in order to modulate 
production of NAPEs/NAEs. 
Modulation of Hrasls-1 by changes in nutritional feeding state would strongly suggest a 
role for this enzyme in regulating the substrate switch between fasted and fed states as a 
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regulator of the NAPE/NAE/ PPAR-α , TRPV1, or GPPR119 signalling pathways, thus regulation 
of Hrasls-1 gene expression under these varying conditions needs to be investigated. One way to 
determine ifHRASLS-1 may play a role during the fed/fasted switch is to analyze the expression 
of the receptors that may be activated downstream of HRASLS-1-regulated NAEs, and the 
expression of the genes that they, in turn, control.  Additionally, determination of whether Hrasls-
1 gene expression is regulated during inflammation is a critical first step in the identification of a 
role for this enzyme in this physiological process.  Finally, neither the concentration of various 
NAEs, nor the expression of Hrasls-1, have been investigated during embryogenesis. Thus 
investigating expression of Hrasls-1 in mouse embryos at varying time points would suggest a 
role for this enzyme during embryological development.  
The aim of the current study is to generate an initial understanding of the physiological 
relevance of the HRASLS-1 enzyme by determiningHrasls-1 expression in different nutritional 
states, during inflammation, and during embryonic development.  Since this area of research is 
extremely novel, the work done here is exploratory but essential in forming the foundation for 
future work in this research domain.  
 
3.2 Objectives 
1. Since I am focused on studies of murine HRASLS-1 gene expression, my initial objective was 
to identify the mouse transcripts that encode for this gene, and to investigate differences in 
their stability using the transcription inhibitor actinomycin D.  
2. To investigate whether this enzyme may play a role in substrate oxidation regulation by 
measuring mRNA expression of Hrasls-1 transcript variants, and genes potentially regulated 
by Hrasls-1-derived NAEs in liver, kidney, white adipose tissue, heart, and brain from fed, 
fasted and re-fed mice.  
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3. To analyze the change in level of NAPE during acute activation of cultured BV2 microglial 
immunocytes, and to analyze whether changes have occurred in levels of Hrasls-1 transcript 
variants, or any of the other known murine iNATs (Hrasls-3 and Hrasls-5) that may mediate 
this effect.  
4. To determine whether changes in Hrasls-1 may play a role in regulating NAPE/NAE in mid to 
late embryonic development by measuring expression of the Hrasls-1 transcript variants in 
differing stages of embryonic development (E10.5, E14.5, E18.5).   
 
3.3 Hypotheses 
1. The Hrasls-1transcript variants have unique 3’ and 5’ UTRs that play a role in stability. Due to 
the significantly longer AU-rich 3’ UTR tail, the 2.9kB transcript will be more unstable and 
rapidly degraded upon transcription inhibition.  
2. The different transcript variants of Hrasls-1will be differentially expressedduring non-fasted, 
fasted, and re-fed states. Due to the greater predicted instability of the 2.9 kb transcript 
variant, I predict that it will show greater variability as a result of its rapid degradation.  
3. Hrasls-1 transcript variant mRNA expression will be increased in fasting 
4.  As a result of increased Hrasls-1 expression in the fasted state, there will be increased mRNA 
expression of receptors activated downstream of the HRASLS-1pathway,including Ppar-α, it’s 
target genes Acox1 and Cpt1, and Scd-1, and Trpv1 mRNA expression will decrease in the 
fasted state.  
5. Expression of the Hrasls-1transcript variants will be induced upon activation of BV2 cells with 
LPS. As a result, NAPE content will increase in microglial BV2 cells as a result of acute 
activation with LPS. 
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6. The different transcript variants of Hrasls-1will be differentially expressedduring embryonic 
development, and the 2.9 kb transcript variant will show greater variability in expression.  
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Chapter 4 
Study Design and Analytical Techniques 
4.1 Study Design: Overview 
In order to target each objective, unique experiments were required; therefore objectives 
were divided into unique studies. In order to characterize the different transcript variants 
identified for HRASLS-1, in study #1, two different primer pairs were designed, that would 
measure the mRNA expression of each transcript variant exclusively.  BV2 cells were grown and 
treated with a transcription inhibitor for various time periods, and then mRNA expression for 
each transcript variant was quantified. Study #2 looked at energy substrate regulation of Hrasls-
1, andwas performed on C57Bl/6J female mice that were either: fed, fasted 16 h overnight, or 
fasted overnight followed by a 4 h period of re-feeding. Tissues were excised, and cDNA was 
extracted in order to measure Hrasls-1 mRNAexpression.In study #3, the expression of HRASLS-1 
under an acute inflammatory response was examined in cultured BV2 cells. Expression of other 
murine HRASLS family members was also determined for comparison with Hrasls-1 expression, 
and specificity of the Hrasls-1 response. Additional BV2 cells were activated and simultaneously 
treated with radiolabeled [C14] palmitate, for quantification of NAPE. For study #4,Hrasls-1 mRNA 
expression was also measured in whole embryos at three mid- to late-stage time points, when 
embryos were visible. Details regarding specific experiments for each study are found within the 
respective section, while commonly used methods are discussed below.  
 
4.2 BV2 Cell Culture 
Microglia are the “resident macrophage-like cells of the central nervous system (CNS)”102, 
have the ability to react within a wide variety of inflammatory neuropathologies102.  As their 
proliferation capacity is limited, they have to be isolated fresh for each experiment103. This has a 
 23 
large impact on overall animal consumption in biomedical research and imposes a significant 
restriction on the use of these cells in research. BV2 cells are a cell line alternative derived from 
raf/myc-immortalized murine neonatal microglia and are the most common used substitute104. 
BV2 microglial cells were maintained and routinely subcultured at 37C and 5% CO2 in DMEM 
(high glucose with L-glutamine and sodium pyruvate) containing 10% FBS and 
penicillin/streptomycin.  
 
4.3 RNA Extraction 
 With reference to the ambion Life Technologies procedure141, previously described within 
the MSc thesis of Ryan Bradley140, RNA was isolated from tissue and embryonic samples using 
1mL TRIzol® reagent, followed by complete homogenization using a Polytron® homogenizer. 
Samples were incubated for 5 minutes at room temperature, in order to allow for dissociation of 
the nucleoprotein complex. Once this was done, 0.2mL of chloroform were added and “shaken 
vigorously by hand” for 15 seconds. Samples were incubated at room temperature once again, for 
2-3 minutes, followed by centrifugation of the samples at 12,000 x g for 15 minutes at 4°C.  Next, 
the aqueous phase of each sample was removed, and placed into a new 1.5mL Eppendorf tube. 
0.5 mL of 100% isopropanol was added to the new tube, and incubated at room temperature for 
10 minutes. Following this, samples were centrifuged at 12,000 x g for 10 minutes at 4°C.  The 
supernatant was then removed from the tube, leaving only the RNA pellet, which was washed 
with 1 mL of 100% ethanol. Before a final centrifugation at 7500 x g for 5 minutes at 4°C, the 
sample was vortexed briefly.  Once centrifugation was complete, samples were air-dried for 
approximately 5-10 minutes, making sure to not dry the pellet.  Finally, the pellet was 
resuspended in 30-50uL DEPC-treated water at 58°C for 12 minutes. RNA concentrations and 
purity were immediately determined using a Nanodrop-2000, and samples were stored at -80°C. 
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4.4 Reverse-Transcriptase (RT) –quantitative PCR  
RNA sample concentrations were adjusted to 2 μg/μl, and complementary DNA (cDNA) 
was produced by reverse-transcription of 1 μg of RNA. RNA was mixed with 1 μL of 10 mMdNTPs 
and 1 μL of oligo(dTs)12-18 and incubated at 65°C for 5 minutes. Once complete, the samples were 
cooled on ice for 1-2 minutes. This was followed by the addition of 6 μL of reaction mix (per 
sample) containing, 4 μL of 5 X first strand buffer, 2μL of 0.1 M DTT. Samples were then 
immediately incubated at 42°C for 2 minutes in order for primers to anneal. The final step 
required the addition of 1uL of Superscript II mix, which consisted of 2 uL of 5X first strand 
buffer, 3 uL of ddH2O, and 5 uL of Superscript II, to each sample. At last, samples were incubated 
in a 42°C water bath for 50 minutes. Once completed, samples were transferred to a prepared, 
elevated water bath at 70°C for 15 minutes. cDNA was stored at -20°C. 
Quantitative real-time PCR was performed using SsoFastEvaGreen PCR Super Mix (Bio-
Rad Laboratories, Mississauga, Canada) with targeted primers (Table 1) or 
PerfeCTaqPCRToughmixLowRox with Taqman predesigned gene expression primers with FAM-
labeled probes (Applied Biosystems) (Table 2). cDNA generated by RT was amplified at a 
reaction volume of 10 μl, by 2-step thermal cycling in a CFX96 Touch™ Real-Time PCR Detection 
System. The initial incubation was 95°C for 3 minutes, followed by 40 cycles of 95°C for 10 
seconds and 55°C for 30 seconds. Following 40 cycles, a dissociation curve was produced by 
increasing the temperature from 60°C to 95°C at a rate of 1°C per minute.Quantitation was 
performed by assessment of relative fluorescence after each cycle. The relative quantity of each 
Hrasls-1 transcript (Ct) was normalized to a group of reference genes by calculating ΔCt = [Ct 
(tissue) – Ct (average of three reference genes)]. The expression of Hrasls-1 transcripts in 
different tissues was calculated relative to the expression of that tissue in the group with the 
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lowest abundance (ΔΔCt). Hrasls-1 gene expression was normalized to an average of 18S, 
actin, and RPII expression within tissues.  
4.5 Primer Design 
The 2.9 kbHrasls-1 transcript variant was amplified with sense primer (5’-
TGGAACTGAGCTGTGAGCAG-3’) and antisense primer (5’-CCAAGGCCTTTGTGCTGAAC-3’). The 
sense primer was located within the 5’-UTR, while the antisense primer was located within the 
coding region. The 0.8 kbHrasls-1transcript variantwas amplified with sense primer (5’-
ATGGAGTCACCCAGGGTCTG -3’) and antisense primer (5’-CCTGCCCAATAGCGAACTCT-3’) that 
were located within the 5’-UTR and coding regions, respectively. Since the 5’UTRs differed 
between the 2.9 kb and 0.8 kb transcripts, this design lead to specific amplification of only one of 
the two transcripts.  Primers for mouse sequence of Hrasls-3, Hrasls-5, Hrasls-1(coding region), -
actin, 18S, and RPII, Trpv1 and Cpt1 were designed with Primer-BLAST program on the NCBI 
website and ordered from Sigma-Aldrich. Primers for the murine sequence of Ppar ,Scd-1 and 
Acox1 were graciously provided by Kristen Marks and the Stark Lab.  
 
4.6 Statistical Analyses 
All statistical analyses were done using Prism6 for Mac. Independent samples t-test was 
used for comparison of NPPE content within BV2 cells, and within the embryonic development 
data between transcript variants. One-way ANOVA was used for comparison between Hrasls-1 
transcript variants as well as between Ppar- Acox1, Cpt1-, Scd-1, and Trpv1 within non-fasted, 
fasted, and re-fed states. One-way ANOVA was also used for comparisons between mRNA 
expression of HRASLS family members, and between Hrasls-1 transcript variants upon activation 
with LPS. Newman-Keul’s Multiple Comparison Testwas used following a significant one-way 
ANOVA result. Significance was inferred when p < 0.05.
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Table 1 Mouse SYBR Green-based primer sequences for RT-PCR  
HRASLS-1 2.9kB Transcript: HRAS-like suppressor 2.9kB, HRASLS-1 0.8kB transcript variant: HRAS-like suppressor 0.8kB 
transcript variant, HRASLS-1- coding: HRAS-like suppressor coding region only, HRASLS-3: phospholipase A2, group XVI, 
HRASLS-5: HRAS-like suppressor family, member 5, 18S: 18S ribosomal RNA, Scd1: stearoyl-Coenzyme A desaturase 1, Acox1: 
acyl-Coenzyme A oxidase 1, Ppar-: peroxisome proliferator activated receptor alpha. Trpv1: transient receptor potential 
cation channel, subfamily V, member 1. Cpt1: carnitinepalmitoyltransferase 1a, liver.  
Gene Genbank 
Accession Number 
Forward Sequence Reverse Sequence 
HRASLS-1 2.9kB 
Transcript 
NM_013751 TGGAACTGAGCTGTGAGCAG CCAAGGCCTTTGTGCTGAAC 
HRASLS-1 0.8kB 
Transcript 
BC048482 ATGGAGTCACCCAGGGTCTG CCTGCCCAATAGCGAACTCT 
HRASLS-1- coding NM_013751/ 
BC048482 
CACAACCCACACCCAGGAGA CACCAAGGCCTTTGTGCTGA 
HRASLS-3 NM_139269 TGTCCTTCCCGGCCACATGG CCCAAGCCTGGAGACCTGAT 
HRASLS-5 NM_025731 GGGTCTTGGATTGCCCTCAA CCGATTAGAACAGGCCGAA 
18S  M11188 GATCCATTGGAGGGCAAGTCT AACTGGAGCAAGTTTAATATACGCTATT 
Scd1 NM_009127.4 TGCGATACACTCTGGTGCTCA CTCAGAAGCCCAAAGCTCAGC 
Acox1 NM_015729.3 GCTGCGGAGACAGGTTGTCATCG GCTCCTTGCGCAGATCGGGATTC 
Ppar-α NM_011144.6 CCGAACATTGGTGTTCGCAGCTGT CAGGGGACAACCAGAGGACCCAG 
Trpv1  AGCCCCACATCTTTGCTACC GACAACAGAGCTGACGGTGA 
Cpt1 NM_013495.2 CCCCGCGAGTCCCTCC AGTCATGATGATCGCCACCC 
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Table 2 Mouse TaqMan-based primer sequences for RT-PCR   
 
 
 
 
Actb: beta actin, RPII: polymerase (RNA) II polypeptide A.  
 
 
 
 
 
 
 
 
 
Gene Primer Reference Number 
Actb Mm00607939_s1 
RPII Mm00839493_m1 
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Chapter 5 
 
Identification of Two Unique Transcript Variants for HRASLS-1 with Unique Stability 
5.1 Introduction  
 
 In order to explore Hrasls-1 mRNA expression within various physiological changes, it is 
important that we first investigate the Hrasls-1 sequence for different transcript variants. Transcript 
variants are generate by alternative splicing during gene expression105. Within this process, exons 
may be included or excluded from the mRNA, creating transcripts that possibly hold opposing roles 
if significant differences are found106. Differences can implicate a range of effects, from biological 
roles to transcript stability.  The purpose of this work was to gain insight on possible factors that 
could be altering the total Hrasls-1 mRNA expression observed. This included transcript variant 
identification and analysis of transcript stability.  
Actinomycin D is a commonly used inhibitor of transcription.  Actinomycin D acts by 
interfering with mRNA synthesis, by preventing elongation of the RNA chain by RNA 
polymerases107.  For cell culture applications, actinomycin D is used at a concentration of 1 µg/ml, 
and is initially dissolved at 1000x concentration in DMSO. Once cells are treated with actinomycin D, 
transcription stops. Essentially what we are left with in each treated plate is the RNA that existed 
prior to actinomycin D treatment, minus the RNA that has been degraded, without the complication 
of continuous input from the nucleus. In this experiment we compared the level of each of the 
Hrasls-1transcript variants at different time points, which is a function of the initial content when 
actinomycin D was added, and the relative degradation rate for a particular transcript. If one 
transcript is more rapidly degraded, the relative level will disappear at a faster rate. 
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5.2 Methods 
BV2 cells were used in this experiment. Cells were grown at 37°C to 80% confluency in 60 mm 
dishes containing DMEM with 10% fetal bovine serum and penicillin/streptomycin. Actinomycin D 
(1 µg/ml) was added to each plate for 0 h (prior to addition of actinomycin D) 0.5 h, 1h, or 2 h. 
Media was then carefully pipetted off, and Trizol ® was added directly to cells for extraction of RNA. 
Complementary DNA (cDNA) was produced by reverse-transcription of 1 μg of RNA. Quantification 
of expression by qPCR provides a relative indication of how much RNA is left after the actinomycin 
D incubation.  
 
5.3 Results 
5.3.1 HRASLS-1 has unique transcripts with identical coding regions but different 5’ and 3’ 
UTR 
We searched the National Center for Biotechnology (NCBI) Genbank database and identified 
two different HRASLS-1 transcript variants with identical coding regions but highly dissimilar 5’ 
and 3’ untranslated regions (UTRs) (Figure 2). Both transcripts had 5’UTRs of a similar length 
(116bp vs. 150 bp), although the nucleotide sequence through this region differed entirely. 
Conversely, the 3’UTR of these transcripts shared sequence identity for the first 139 bp after the 
stop codon, but the longer transcript contained an additional 2,157 bp beyond this sequence, 
creating a large difference in relative size of the transcripts (0.8 kb versus 2.9 kb). Differences in 
transcript size, particularly in the untranslated regions, can affect transcript stability and rates of 
translation. The presence of two highly dissimilar transcripts encoding the same protein suggests 
that regulation during different conditions may also vary, and understanding this regulation may 
give insight into the physiological role of this enzyme. Analysis was done on the relative stability of 
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these transcripts, and then the relative expression of these transcripts during changing metabolic 
states, during inflammation activation, and during different periods of embryonic development. 
 
5.3.2 The Half-life of the Hrasls-1 0.8 kb transcript is shorter than that of Hrasls-1 2.9 kb 
transcript variant 
We treated BV2 cells with actinomycin D, and harvested cells for RNA analysis at 0, 0.5, 1, 
and 2 h time points. Our data indicates that the 0.8 kb transcript was degraded faster than the 2.9 kb 
transcript, since the half life of this transcript was reached approximately twice as fast as that of 
Hrasls-1 2.9kB transcript (time point 0.5 h vs 1 h)(Figure 3). Interestingly, the 2.9 kb transcript 
showed a slight initial elevation in mRNA expression from time point 0 h to time point 0.5 h. 
Similarly, the 0.8 kb transcript variant also demonstrated a slight elevation from time point 1 h to 2 
h.  
 
5.4 Discussion 
 
Although both transcripts share identical sequences in the proximal portion of the 3’ UTR, 
the longer transcript is defined by an additional 2 kb of mRNA continuing downstream of the coding 
region. This extended UTR is adenylate-uridylate-rich. Adenylate/uridylate-rich elements (AREs) 
are “found in the 3’ untranslated region (UTR) of many messenger RNAs (mRNAs) that code for 
proto-oncogenes, nuclear transcription factors and cytokines” 108. They communlyhave  several 
copies of the pentanucleaotide, AUUUA, and a high concentration of ‘U’ and ‘A’ residues108. They are 
associated with  RNA destabilizing ability in mammalian cells108.  It is important to note that “ARE-
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directed mRNA degradation is influenced by many exogenous factors”108, such as transcription 
inhibitors.  
 Due to the AREs found in the 3’ UTR of the 2.9 kb transcript variant, this Hrasls-1 transcript 
should show reduced stability in comparison to the 0.8 kb transcript variant. Contrary to my 
hypothesis, cells incubated with actinomycin D showed a more rapid drop in the percentage of 
remaining Hrasls-1 transcript variant 0.8 kb in comparison to the 2.9 kb transcript. Although the 
general consensus in the literature108 states that these AREs found in the 3’ UTR of mRNAs would 
target the transcript variant for rapid degradation, various factors can counter the ARE function. 
Depending on the specific class and sequence of ARE present, the destabilizing ability may be 
different, as it is portrayedin a “cell-type specific” manner108. One example illustrates how IL-3 AREs 
are required in a tumour cell line for the destabilization of IL-3 mRNA, while the stability of IL-4 
mRNAs, containing a different class of AREs, remains unchanged in the same cells108. This could 
imply that AREs present at the 3’ UTR of the 2.9 kb transcript variant may not be acting to 
destabilize mRNA in the BV2 cell line. Therefore, replicating the experiment on several cell lines 
would be beneficial in gaining a greater understanding of the role of the AREs present. Similarly, 
cloning of the different 3’ UTRs, and performing mutagenesis of some of the AREs, would provide 
greater insight into the role of some of the individual sequence elements. 
Further analysis of mRNA levels during the time course of actinomycin D exposure indicated 
an interesting phenomenon. We observed a small initial increase in mRNA level of the 2.9 kb 
transcript at 0.5 h after transcription arrest.  Theoretically, when transcription is inhibited by 
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actinomycin D, there should not be any novel formation of mRNAs. Therefore mRNA levels after 
actinomycin D treatment should not be higher than mRNA levels seen at time point 0h. Evidence 
from other experimental reports suggests, however, that this is not always the case, and that there 
are some limitations to the use of transcriptional inhibitors such as actinomycin D for the study of 
mRNA stability. Due to “feedback loops”, during transcript inhibition, transcription of a small group 
of genes may be induced for protection against genotoxic stress109. This may lead to the 
accumulationof certain genes when inhibitors are introduced at moderate concentrations110. 
Secondly, the binding activity of the ARE- binding proteins can “inversely or proportionally” relate 
to the stability of ARE-containing mRNAs108. One theory discusses how during transcription 
inhibition, ARE-binding proteins can travel between the nucleus and cytoplasm, causing a 
disturbance in the cytoplasmic concentration of these proteins108.  Consequentially, ARE-protein 
complexes, necessary for ARE-directed mRNA decay, may be interrupted108. 
Taken together, our results indicate unique 5’- and 3’-UTRs and a unique stability for each 
transcript variant, suggesting that differential regulation of alternate transcripts may allow cells to 
‘fine-tune’ control of this gene, in order to respond to rapidly changing conditions 
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Figure 2. Nucleotide alignment of both Hrasls-1 Transcripts. 792bp: Hrasls-1 0.8kB transcript 
variants, 2915bp: Hrasls-1 2.9kB transcript variant. Coding region denoted by shaded area.  
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Figure 3. mRNA content of Hrasls-1 transcript variants in BV2 cells treated with actinomycin D for 
increasing periods of time. Data were normalized to beta-actin and expressed relative to the mRNA 
expression at time point 0 (n = 4). 2.9kB: HRASLS-1 2.9kb transcript variant, 0.8kb: HRASLS-1 0.8kb 
transcript variant 
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Chapter  6 
Differences in HRASLS-1 Transcript Variant mRNA Expression in Various Tissues During 
Non-Fasted, Fasted, and Re-fed States 
6.1 Introduction 
Energy metabolism impacts all cellular functions. The human body goes between a fasted 
and non-fasted state happens several times throughout the day, depending on the incoming supply 
of nutrients, and requires a major shift in substrate regulation involving hundreds, if not thousands 
of different cellular processes. Extracellular factors communicate signals between tissues to 
regulate substrate handling and energy balance111,112. These signals are often produced at the 
cellular level through the action of enzymes. Modulation of the expression of genes encoding 
regulatory enzymes allows rapid tissue-specific responses. Through regulation of 
mRNAtranscription, splicing, stability, and translation the amount of protein formed can be 
controlled, at least in part113.  If these regulating factors are incorrectly controlled, it may lead to an 
abnormal metabolic state, with health implications including obesity development and associated 
co-morbidities. Therefore, identifying genes that mediate signalling of energy balance is important 
for understanding both normal and disregulated physiology. Many of the genes that function in 
signalling pathways pertaining to energy homeostasis will undergo expression regulation in order 
to respond to changing substrate and energy availability. A role for NAEs in regulation of food 
intake9,114 and substrate oxidation115 has previously been identified, although enzymes regulating 
their synthesis have not yet been investigated during the different nutritional states.  
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6.2 Methods 
6.2.1 Mouse Care and Tissue Harvesting 
C57Bl/6J mice were bred and housed at the central animal facility accordingto standards of 
the Canadian Council on Animal Care and in accordance with an approved animal use protocol 
(AUPP 12-15). Female mice age 15-18 weeks of age were subjected to changing feeding conditions 
prior to euthanasia in accordance with animal use protocol (AUPP 12-08) that received ethical 
approval by the University of Waterloo Animal Ethics Committee. Mice were fed a standard chow 
diet with ad libitum access to food (non-fasted) or were fasted overnight for 16 h (fasted), or were 
fasted overnight for 16 h followed by a 4 h period of (re-feeding). Following euthanasia by cervical 
dislocation, mice were rapidly dissected and excised organs, specifically liver, WAT, kidney, heart 
and brain, were snap-frozen in liquid nitrogen, and then stored at -80°C prior to RNA isolation. 
 
6.3 Results 
6.3.1Both transcript variants of Hrasls-1 in the liver exhibit up-regulation in the fasted state 
The relative expression of Hrasls-1 transcript variants (0.8 kb and 2.9 kb) was determined in 
cDNA prepared from liver.  Samples were analyzed by the deltaCt method, and were normalized to 
an average of three different housekeeping genes used as loading controls (-actin, 18S, and RPII), 
in order to minimize variation. Transcript levels were expressed as fold-difference relative to the 
mRNA expression of the 2.9kb transcript variant in the non-fasted state. Results showed a 
significant up-regulation of both transcript variants in the fasted state in comparison to the non-
fasted and re-fed state (Figure 4).  
The 2.9kb Hrasls-1 transcript variant was 15-fold higher in the fasted state when compared 
to the non-fasted state. After 4 h of re-feeding, we see a significant 6-fold down-regulation of 
expression relative to fasting. Indeed, in the re-fed state, the 2.9kb Hrasls-1 transcript variant shows 
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an almost complete quantitative return to mRNA levels similar to those of the non-fasted state. This 
is evidenced by the fact that there is no significant difference in expression level between Hrasls-1 
transcript variant 2.9kb in the non-fasted and re-fed state.  
When analyzing the expression of Hrasls-1 0.8kb transcript variant in the liver, results 
indicate a similar pattern of regulation, but an even greater magnitude of effect. The Hrasls-1 0.8kb 
transcript variant showed nearly a 30-fold increase in expression from the non-fasted to the fasted 
state. Similar to the 2.9kb transcript variant, in the re-fed state the 0.8kb transcript variant shows a 
decrease in mRNA expression, adjusting back to levels similar to those seen in the non-fasted state. 
The Hrasls-1  0.8kb transcript variant was down-regulated 8-fold  from the fasted to the re-fed state. 
There was no significant difference between Hrasls-1 0.8kb transcript variant mRNA expression 
between the non-fasted and re-fed state, indicating that a 4 h period of re-feeding was sufficient to 
return Hrasls-1 0.8 kb transcript expression to the non-fasted baseline levels.  
Our results show no significant difference in the relative expression of Hrasls-1 0.8kb and 2.9 
kb transcript variants in either the non-fasted or re-fed states. However, in the fasted state, where 
both transcripts showed highest mRNA expression, there was a significant 3.7-fold difference 
between transcript variants.  
 
6.3.2The 0.8 kb Hrasls-1 transcript is the predominant variant in kidney in all measured 
states, although both variants are up-regulated by fasting 
Expression of the 2.9 kb and 0.8 kb transcript variants of Hrasls-1 was analyzed in kidney 
cDNA from non-fasted, fasted, and re-fed mice and normalized to an average of loading controls (-
actin, 18S, and RPII), then expressed relative to the level of the Hrasls-1 2.9kb transcript variant in 
the non-fasted state (Figure 5). In the kidney, both transcript variants were up-regulated in the 
fasted state.  
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The Hrasls-1 2.9 kb transcript variant showed an 18-fold increase from the non-fasted to the 
fasted state. This was followed by a significant 6-fold decrease in expression from the fasted to the 
re-fed state. This decrease was not as extensive as the up-regulation seen between the non-fasted 
and fasted state, but it was enough of a decrease that there was no significant difference between 
the levels of expression of the 2.9kb transcripts in the re-fed and non-fasted states. Thus in kidney, 
similar to liver, a 4 h period of re-feeding appears to be sufficient to return levels of the 2.9 kb 
transcript to baseline non-fasted levels.    
 The Hrasls-1 0.8kb transcript variant increased 11-fold from the non-fasted to fasted state. 
From the fasted to re-fed state, there was a significant down-regulation of transcript variant 
expression, by 4-fold. This resulted in an intermediate level of expression of the Hrasls-1 0.8kb 
transcript variant that fell between the non-fasted and fasted states, and was significantly different 
from both. A 4 h period of re-feeding, therefore, was not sufficient to completely return expression 
levels of the 0.8 kb transcript variant to baseline levels seen in the non-fasted state, with mRNA 
levels remaining approximately 2-fold higher in re-fed kidney than in non-fasted kidney.  
Within the kidney, results indicate a significant difference in mRNA expression levels 
between Hrasls-1 0.8kb and 2.9kb transcript variants in the non-fasted, fasted, and re-fed states. 
Interestingly, the relative difference (~4-fold) between levels of the transcript variants was least in 
the fasted state when levels of both transcripts were most elevated, but greatest in the non-fasted 
and re-fed states, when differences of approximately 7-fold were evident between 0.8 kb and 2.9 kb 
transcripts.  
 
6.3.3  Hrasls-1  transcript variants are induced in the fasted state in white adipose tissue  
Hrasls-1  transcript variant expression was analyzed in adipose tissue, and values were 
normalized to an average of three loading controls, -actin, 18S, and RPII.  Values are expressed 
relative to expression of the Hrasls-1 0.8 kb transcript variant in the non-fasted state (Figure 6). 
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Both Hrasls-1 transcript variants were up-regulated in the nutrient deprived, fasted state. This is in 
agreement with effects observed in kidney and liver.  
The Hrasls-1 2.9kb transcript showed a moderate up-regulation of 6-fold from the non-fasted 
to the fasted state. The 0.8kb transcript variant, however, showed a sizeable increase in expression 
of approximately 85-fold from the non-fasted to the fasted state. This result suggests that 
modulation of the Hrasls-1 0.8 kb transcript variant during feeding is the principle transcript variant 
for up-regulation of HRASLS-1 levels. In the re-fed state, the 0.8 kb transcript variant was able to 
return to levels similar to those seen in the non-fasted state. Hrasls-1 2.9 kb transcript variant did 
not normalize to values seen in the fasted state, and showed a moderate level of expression with a 
3-fold difference from the non-fasted state, and a 2-fold difference from the fasted state. 
Expression levels of the 2.9 kb and 0.8 kb transcript variants were significantly different in 
the up-regulated fasted state. Results indicate that expression of the Hrasls-1 0.8kb transcript 
variant was 4-fold higher than that of the 2.9 kb transcript in fasted white adipose tissue. In the non-
fasted state the levels of the transcript variants were not significantly different, indicating that 
baseline level expression of both transcript variants is similar.  
 
6.3.4Hrasls-1transcript variants within the heart show similar expression levels between 
different measured states 
Expression of heart Hrasls-1 transcript variants was normalized to an average of 18S and 
RPII expression as loading controls, and levels are given as fold-difference relative to the Hrasls-1 
2.9kb transcript variant in the non-fasted (ad libitum fed) state.  
 Our results agree with the concept of preserving constant energy and metabolite levels 
(Figure 7).  They indicate that there is no significant effect on heart Hrasls-1 mRNA expression 
during changes between nutritional states.  
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 Furthermore, there was no significant difference between the Hrasls-1 transcript variants 
within the non-fasted, fasted state, or re-fed sate.  
 
6.3.5 Expression of Hrasls-1 transcripts showed no significant variation in the brain 
 Analysis of brain Hrasls-1 transcript variant expression (normalized to -actin, 18S, and 
RPII), expressed in relation to the 0.8 kb transcript in the non-fasted state, illustrated that there 
were no significant differences between changing nutritional states, or between levels of the 
individual transcripts within any given state (Figure 8).  The high degree of conservation of 
regulation of the Hrasls-1 transcript variants differs from any other tissue tested except heart, and 
may be related to the relative isolation and homeostatic independence of brain tissue.  
 
6.3.6PPAR-,Acox1, andTRPV1 mRNA expression were significantly increased in the fasted 
state within the liver 
The relative expression of Ppar-,Acox1, Cpt1a, Trpv1 and Scd-1, were also determined in 
cDNA prepared from liver, and normalized to -actin, 18S, and RPII.  Transcript levels were 
expressed as fold-difference relative to control mRNA expression Results showed a significant up-
regulation of Ppar-, Acox1, and Trpv1 mRNAwithin the fasted state (Figures 9,10,13), while Scd-1 
and Cpt1expression did not show significant differences (Figures 11, 12).  
Ppar- mRNA expression was significantly increased 3-fold from the non-fasted to the fasted 
state, and a significant 31-fold decrease was observed from the fasted to re-fed state. This resulted 
in no significant difference in Ppar- mRNA expression between the non-fasted and re-fed states.  
Expression of Acox1 showed a similar pattern of regulation within the non-fasted, fasted, and 
re-fed states. Acox1 mRNA expression resulted in a significant 33-fold increase from the non-fasted 
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to the fasted state, and a significant 5-fold reduction in expression from the fasted to the re-fed 
state. Again, no significant difference was observed between the non-fasted and re-fed states.  
mRNA expression of Trpv1 was significantly different in all three feeding states analyzed. 
mRNA expression was lowest in the non-fasted state, followed by an intermediate 26-fold induction 
in the re-fed state. The fasted state displayed the greatest levels of Trpv1 mRNA expression, 
resulting in a 69-fold induction, relative to the non-fasted state.   
 
6.3.7  mRNA expression of receptors known to be activated by PEA, OEA, and SEA are not 
significantly changed in different nutritional states within the kidney  
 Expression of Ppar-,Acox1, Cpt1a, Trpv1 and Scd-1were analyzed in kidney cDNA from non-
fasted, fasted, and re-fed mice and normalized to an average of loading controls (-actin, 18S, and 
RPII), then expressed relative to either the non-fasted or fasted state (Figures 14-17).mRNA 
expression of  Ppar-,Acox1, Trpv-1, and Scd-1 showed no significant difference within the kidney at 
either the non-fasted, fasted, and re-fed state.  
 
6.3.8Ppar-and target gene Acox1are both significantly up-regulated in the fasted state 
within white adipose tissue 
Within white adipose tissue, Ppar-,Acox1, Trpv1 and Scd-1 mRNA expression was quantified 
and normalized to an average of three loading controls, -actin, 18S, and RPII.  Values are expressed 
relative to the expression of each gene of interest, in the lowest nutritional state. Analysis indicates 
that both Ppar-andAcox1 were significantly up-regulated in the fasted state (Figures 18,19), while 
there was no significant change in mRNA expression of Trpv1 and Scd-1(Figures 20,21).  
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Similar to the liver and kidney, Ppar-mRNA expression was significantly different between 
the non-fasted and fasted states, and between the fasted and re-fed states, showing a 6-fold 
increase, and a 10-fold decrease respectively.  
Acox1 mRNA expression increased 4-fold from the non-fasted to the fasted state. 
Acox1decreased  4-fold from the fasted to re-fed state. Both Ppar- andAcox1 showed no significant 
difference in mRNA expression between the non-fasted and re-fed states within WAT.  
As mentioned, Trpv1 and Scd-1 mRNA expression within WAT showed no significant 
difference, although Trpv1 expression was  completely undetected within the fasted state.  
 
6.4 Discussion 
With respect to energy supply during a deficit state, the TAG stored in adipose tissue are an 
enormous reservoir of metabolic fuel. Adipocytes have an ongoing ability to synthesize and break 
down these TAGs, depending on the body’s current energy demands116. They provide a fuel reserve 
that can be mobilized by lipolysis during food scarcity, releasing fatty acids for oxidation and energy 
in other organs116. In the present work, fasting significantly induced both Hrasls-1 transcript 
variants, strongly suggesting a role for this enzyme in adipocyte biology. Although the functional 
significance of this induction must still be determined in future studies, possible effects are 
suggested by knowledge of the adipose-specific action of the NAEs that would likely be produced 
downstream of HRASLS-1. In adipocytes, OEA stimulates lipolysis and increases the release of 
NEFAs in a “dose-dependent” manner117. OEA also increases -oxidation at least in part through 
activation of PPAR-α8. Additionally, OEA is an agonist of the capsaicin receptor TRPV1, which has 
been found inpreadipocytes where its activation inhibits preadipocyte differentiation and 
adipogenesis118. Thus, induction of Hrasls-1 may help to reduce adiposity through regulation of 
NOPE/OEA synthesis. Induction of Hrasls-1 may also help to reduce adiposity through regulation of 
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the NPPE/PEA/ PPAR-α pathway that activates -oxidation in adipocytes114(Appendix B (A.)).  A 
potential role for HRASLS-1 in adipocyte differentiation, lipolysis regulation, and -oxidation, is 
therefore suggested by the present study, indicating that future work on the role of HRASLS-1 in 
this tissue is merited. 
Analysis of genes involved in fat metabolism indicated that within WAT, Ppar-and Acox1 
mRNA expression, increased within the fasted state.  Since both of these proteins play a role within 
-oxidation and lipolysis, these results further confirm the prospective role of HRASLS-1 
synthesizing PPAR--activating NAEs, to enhance -oxidation and lipolysis within WAT.Trpv1 
mRNA expression was not increased during the fasted state, although further analysis such as 
activity assays, and protein concentrations under changing nutritional states must be done in order 
to make any conclusive decisions with regards to its role downstream of HRASLS1.  
Under changing metabolic conditions, the Hrasls-1 transcript variants shared a similar 
relative pattern of expression within the liver and kidney. In the re-fed state, liver and kidney mRNA 
levels of both Hrasls-1 transcript variants showed a significant down-regulation from the fasted 
state. Within the liver, a 4 hour re-feeding period following an overnight 16 hour fast, was sufficient 
in bringing the expression of both Hrasls-1 0.8 kb and 2.9 kb transcripts back to levels seen within 
the non-fasted state.  In the kidney, both transcripts were significantly down-regulated upon the 
reintroduction of nutrients, although only the 2.9 kb transcript returned to non-fasted levels by 4 
hours. What this indicates is a rapid metabolic adaptation once nutrients are re-introduced. In both 
tissues there was also a significant induction of both Hrasls-1 transcripts from the non-fasted state 
to the fasted state. The liver is a major regulator of energy metabolism within the body119. One of its 
primary roles is the synthesis and repackaging of fuel components for use by other organs. The 
transition from a non-fasted to fasted state changes the equilibrium of hepatic lipid metabolism. In a 
non-fasted state, circulating glucose and insulin are high leading to an increase in hepatic plasma 
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glucose and the de novo synthesis of fatty acids119. Consequentially, hepatic TAG synthesis is 
increased, and β-oxidation of fatty acid is inhibited119. At this time, the liver is in a “lipogenic” 
state119. Alternatively, in a fasted state, the glucose and insulin concentrations fall, driving TAG 
breakdown, for fatty acid release from adipose tissue and increasing plasma fatty acid levels119. In 
peripheral tissues, such as the liver, fatty acids are then hydrolyzed as needed to supply fuel 
substratesthrough β-oxidation to relieve energy shortages119. At this time, the liver in a“lipolytic” 
state119. Similar regulation has been observed in the kidney120.  Although the kidney is also a site for 
lipoprotein synthesis and secretion121, it was reported that NEFA and esterified FA are largely 
assimilated by the kidney in the state of starvation120.  Along with the liver, in the fasted state the 
kidney is also in a lipolytic state, with increased dependency on -oxidation of NEFAs as a fuel 
source.  
Our data indicates that Hrasls-1 is induced in response to fasting within the liver as well as 
within the kidney. A possible implication of this effect is that HRASLS-1 may play a role in 
stimulating NAPE/NAE signalling to increase -oxidation, in a state where glucose stores have been 
depleted, and NEFA are more abundant. Several NAEs, including PEA and OEA, are known to 
activate PPAR- αthat is a potent activator of -oxidation114.  OEA has been shown to enhance fatty 
acid oxidation in dissociated hepatocytes, through activation of PPAR-α122. OEA is also able to 
induce the expression of PPAR-α-regulated genes that participate in fatty acid utilization, including 
FAT/CD36 and FABP that mediate uptake of fatty acids, and UCP-2 and UCP-3 that mediate the 
dissipation of excess energy following fatty acid oxidation. Induction of HRASLS-1 may also increase 
the downstream synthesis of SEA. SEA is able to reduce liver SCD-1 mRNA expression98, and in the 
fasted state may be doing so in order to facilitate increased liver fatty acid oxidation and decreased 
lipogenesis. Therefore, since Hrasls-1 is clearly regulated in liver and kidney, it suggests that this 
enzyme and its associated signalling pathways may play an essential role in mediating the metabolic 
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switch between fasting and re-feeding that is necessary to ensure that energy demands continue to 
be fulfilled upon nutrient withdrawal (Appendix B (B.)).It is important to mention that although 
the potential relevance of GPR119 was introduced as a possible mediator of the HRASLS-1 pathway, 
our results have suggested otherwise. GLP-1, activated by GPRR119, stimulates insulin secretion 
and promotes nutrient metabolism, essentially delaying further nutrient intake69,70, a response that 
is related to the non-fasted state. Since our results show Hrasls-1 to be down-regulated in the non-
fasted state, it suggests that its does not mediate the NOPE/OEA/GRP119 pathway. Thus, GPR119 
may not be a significant mediator of HRASLS-1-associatedsignalling of nutritional regulation.  
Since HRASLS-1 may act through regulation of PPAR-α or TRPV1, we tested expression of 
these genes and others that they regulate inliver and kidney as well. It is important to note that 
CPT1αis the liver isoform of the enzyme, and its expression is limited within other tissues123. If key 
enzymes and receptors involved in -oxidation and fat metabolism were up-regulated, in the same 
manner as Hrasls-1, this would confirm the possibility that the HRASLS-1 pathways could be 
activating these proteins downstream. Results indicated that within the liver, mRNA expression of 
Ppar-α, Acox1, and Trpv1 were significantly up-regulated within the fasted state, relative to both the 
non-fasted and re-fed states. Thus, HRASLS-1 can be increasing the synthesis of OEA and PEA to 
activate both TRPV1 and PPAR-α.  As mentioned earlier, Acox1 is a classic target gene of PPAR-α124, 
therefore it’s up-regulation is expected to follow that of PPAR-α . Furthermore, the ACOX1 protein is 
the first enzyme in the fatty acid -oxidation pathway, catalyzing the desaturation of acyl-CoAs119. 
Thus, it would be essential in the oxidation of incoming NEFAs during the fasted state. 
Unfortunately we saw no significant difference in expression of Scd-1, and Cpt1α mRNA. This does 
not rule out the possibility of SEA activation via HRASLS-1, but simply imposes for further 
investigation. Within the kidney, we did not see any significant change in mRNA expression of all 
genes investigated, thus we are unable to make further speculations about the involvement of 
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HRASLS-1 through these receptor-mediated pathways.  
Our results suggest that HRASLS-1 may play a significant role in activating extra-adipose 
fatty acid oxidation, and that the increase in activation may be due, at least in part, to its role in 
helping to elevate levels of circulating NEFAs from adipose tissue during the fasted state. There is a 
widespread acceptance in the literature that NEFAs can mediate many adverse metabolic affects125. 
In obesity a significant elevation of NEFA concentrations are found due to the increase in adipose 
tissue mass125. An increase in circulating NEFA molecules will force an increased uptake of NEFAs 
into peripheral tissues. This will aggravatelipid accumulation in other tissues, leading to a 
progression of obesity-linked diseases. It would be of great interest to investigate whether HRASLS-
1 overexpression could decrease this lipid accumulation by enhancing fatty acid oxidation. It is 
possible that HRASLS-1 pathway may also up-regulate the expression of uncoupling protein UCP-3 
through increased production of OEA. UCP-3 has been shown to play a role in fuel source 
management and energy metabolism, leading to improved body weight regulation126. Over 
expression of HRASLS-1 in obese model would allow us to examine this theory and further analyze 
the role of HRASLS-1in fatty acid oxidation. These findings could eventually hold therapeutic 
relevance. 
Both the heart and brain are energy-demanding tissues, which require a continuous supply 
of energy, regardless of non-fasted, fasted, or re-fed state. The heart has a high rate of energy 
production and turnover that is required to maintain its continuous mechanical work, and any 
perturbations in energy-generating processes may therefore affect contractile function directly127.  
In contrast, the brain lacks lipid fuel stores and hence requires a continuous supply of glucose for 
energy production128.  Even the slightest perturbations in energy supply to the brain can be 
damaging to its overall function138. Thus, maintaining glucose/energy metabolism in an unchanged 
manner is critical for brain health. With that said, in tissues that are highly reliant on a constant 
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supply of substrate, such as the heart and brain, energy homeostasis is relatively constant. It is 
possible that the role of HRASLS-1 in these tissues does not show significant difference between the 
changing metabolic states, because energy metabolism does not need further activation.  
Our results indicated no difference in the expression of either Hrasls-1transcript variant in 
the brain, nor the heart, in different measured states. In addition, the heart and the brain showed 
similar effects, where no significant change was seen with either transcript at either state. 
Interestingly, this suggests the possibility that induction of Hrasls-1 could be mediated by changes in 
glucose, since we see less of a change in HRASLS-1 in environments where glucose supply is 
typically unchanged. Demand for glucose supply in the brain and heart is relatively stable. Hence, 
this may help to mediate the lack of Hrasls-1 flux during transition between the different states. 
Additional studies will clearly be required to test this idea. 
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Figure 4.Liver mRNA content of Hrasls-1 transcript variants under different nutritional states. Data 
are expressed relative to the mRNA expression of the Hrasls-1 2.9 kb transcript variant in the non-
fasted state (n = 6) and have been normalized to an average of housekeeping genes (-actin, 18S, 
and RPII). Significant expression differences are denoted by *P<0.05.  2.9 kb: Hrasls-1  2.9 kb 
transcript variant, 0.8 kb: Hrasls-1 0.8 kb transcript variant. 
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Figure 5. Kidney mRNA content of Hrasls-1 transcript variants in different nutritional states. Data 
are expressed relative to the mRNA expression of the Hrasls-1 2.9kB transcript variant in the non-
fasted state (n = 3-5), and normalized to the average expression of three housekeeping genes (-
actin, 18S, and RPII). Significant expression differences are denoted by *P<0.05. 2.9kB: Hrasls-1  
2.9kB transcript variant, 0.8kB: Hrasls-1 0.8kB transcript variant. 
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Figure 6. White adipose tissue mRNA content of Hrasls-1 transcript variants in different nutritional 
states. Data are expressed relative to the mRNA expression of the Hrasls-1 0.8 kb transcript variant 
in the non-fasted state, and normalized to the average expression of three housekeeping genes (-
actin, 18S, and RPII) (n=3). Significant expression differences are denoted by *P<0.05. 2.9 kb: Hrasls-
1 2.9 kb transcript variant; 0.8 kb: Hrasls-1 0.8 kb transcript variant. 
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Figure 7. Heart mRNA content of Hrasls-1 transcript variants under different nutritional states. 
Data are expressed relative to the mRNA level of the Hrasls-1 2.9kB transcript variant in the non-
fasted state (n = 4-6), and normalized to housekeeping genes 18S and RPII. 2.9kb: Hrasls-1 2.9kB 
transcript variant; 0.8 kb: Hrasls-1 0.8kB transcript variant. 
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Figure 8. Brain mRNA content of Hrasls-1 transcript variants in different nutritional states. Data are 
expressed relative to the mRNA expression of the Hrasls-1 0.8 kb transcript variant in the non-
fasted state (n = 3-4), and normalized to housekeeping genes (-actin, 18}S, and RPII). No significant 
differences were observed between transcript levels or among groups. Hrasls-1 2.9 kb transcript 
variant, 0.8 kb Hrasls-1 0.8kB transcript variant. 
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Figure 9. Liver mRNA content of Ppar- under different nutritional states. Data are expressed 
relative to the mRNA levels in the re-fed state (n = 2-3), and normalized to housekeeping genes (-
actin, 18S, and RPII). 
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Figure 10. Liver mRNA content of Acox1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 2-3), and normalized to housekeeping genes 
(-actin, 18S, and RPII). *P<0.05. 
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Figure 11. Liver mRNA content of Cpt1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the fasted state (n = 3), and normalized to housekeeping genes (-
actin, 18S, and RPII). 
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Figure 12. Liver mRNA content of Scd-1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 2-4), and normalized to housekeeping genes 
(-actin, 18S, and RPII). 
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Figure 13. Liver mRNA content of Trpv1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 3-5), and normalized to housekeeping genes 
(-actin, 18S, and RPII).  *P<0.05. 
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Figure 14. Kidney mRNA content of Ppar- under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 3-5), and normalized to housekeeping genes 
(-actin, 18S, and RPII). 
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Figure 15. Kidney mRNA content of Acox1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the fasted state (n = 6), and normalized to housekeeping genes (-
actin, 18S, and RPII). 
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Figure 16. Kidney mRNA content of Scd-1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the fasted state (n = 3), and normalized to housekeeping genes (-
actin, 18S, and RPII). 
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Figure 17. Kidney mRNA content of Trpv1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 3-4), and normalized to housekeeping genes 
(-actin, 18S, and RPII). 
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Figure 18. WAT mRNA content of Ppar-under different nutritional states. Data are expressed 
relative to the mRNA levels in the re-fed state (n = 3-6), and normalized to housekeeping genes (-
actin, 18S, and RPII). *P<0.05. 
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Figure 19. WAT mRNA content of Acox1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 2-4), and normalized to housekeeping genes 
(-actin, 18S, and RPII). *P<0.05. 
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Figure 20. WAT mRNA content of Scd-1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 3-5), and normalized to housekeeping genes 
(-actin, 18S, and RPII). 
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Figure 21. WAT mRNA content of Trpv1 under different nutritional states. Data are expressed 
relative to the mRNA levels in the non-fasted state (n = 2-4), and normalized to housekeeping genes 
(-actin, 18S, and RPII). 
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Chapter 7 
 
iNAT mRNA Expression and [C14 ]NAPE Content in BV2 Microglia Treated with LPS 
 
7.1 Introduction 
 
Microglia are immunocytes found in the central nervous system that function similarly to 
macrophages in the periphery129. They are activated by a variety of stimuli and function as the 
primary cellular mediator of neuroinflammation129. As the “macrophages of the central nervous 
system”, microglia are responsible for clearing foreign invading pathogens as well as clearing 
damaged cells resulting from mechanical, chemical, or biological trauma. In response to direct 
activation by foreign antigens, such as lipopolysaccharide (LPS), or to proinflammatorysignalling by 
cytokines, microglia undergo a series of major changes to an activated phenotype that includes 
increased formation of fine processes (filopodia) 130, increased lytic capabilities131, and increased 
secretion of cytokines. Lipids may play roles as structural and bioenergetic elements, as well as 
signalling elements in these processes. In particular, NAEs are known to be involved in the 
resolution of inflammation, by activating receptors that inhibit proinflammatory cytokines and 
transcription factors67,88. Identification of enzymes involved in inflammation, and in particular in 
signalling inflammation resolution, has major implications for the treatment of multiple chronic 
diseases with inflammatory components, ranging from rheumatoid arthritis to Crohn’s disease to 
Alzheimer’s disease, cardiovascular disease, and diabetes 53,132,133. 
 
7.2 Methods 
7.2.1 BV2 Cell Culture  
BV2 cells express toll-like receptor 4 and can be activated by treatment with LPS134. LPS 
(Sigma Aldrich, Mississauga, Canada, #L6529-1MG) was dissolved in DMEM at 1 mg/ml, then 
diluted in DMEM at 1000 concentration (1 g/ml) prior to addition to cells. 
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7.2.2 Incorporation of [14C]palmitate into cellular NPPE  
BV2 cells were grown at 37°C to 80% confluency in 60-mm dishes containing DMEM with 
10% fetal bovine serum and penicillin/streptomycin. Labeling medium (6 ml per plate) was 
prepared by mixing 2.0 μCi of [14C]palmitic acid per dish with 0.6 ml FBS per dish to allow the fatty 
acid to complex with bovine serum albumin (BSA). The fatty acid-BSA-FBS mixture was then diluted 
1:10 with DMEM, and apportioned equally into two tubes. LPS (dissolved in DMEM) was added to 
one tube, to a final concentration of 1 g/ml, so that half of the plates were treated with radioactive 
fatty acid plus LPS, and half of the plates were treated with radioactive fatty acid without LPS 
(control medium). At time point 0, medium was removed from BV2 cells, and replaced with labeling 
medium for a period of 18 h. Media was then carefully pipetted off, and cells were washed and 
harvested by trypsinization, with the resulting mixture transferred into glass tubes. Any remaining 
cellular material was collected by washing plates with an additional 100 μL PBS, and this was added 
to the harvested cell suspension for total lipid extraction.  
 
7.2.3 Lipid Extraction  
Total lipids were extracted from harvested cells by the method of Bligh and Dyer135. Briefly, 
cells harvested in trypsin/PBS were mixed with methanol: chloroform (2:1) (1.9 ml /0.5 ml of 
sample) and vortexed vigorously for at least 30 seconds. Chloroform was added at 0.625 ml/0.5 ml 
of initial sample volume, and samples were vortexed again vigorously for >30 seconds. Deionized 
H20 was added next (0.625 ml/0.5 ml of sample), and samples were mixed thoroughly by vortexing. 
Samples were centrifuged for 5 minutes at 1500 × g at room temperature in order to separate 
aqueous (top) and organic (bottom) phases. The organic phase was recovered into a new glass tube, 
and evaporated under a stream of N2 gas prior to separation by thin layer chromatography. 
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7.2.4 Thin Layer Chromatography – Resolution of Polar Lipids 
Organic samples dried under nitrogen gas were carefully dissolved in 50 L of chloroform 
and spotted onto a silica-coated glass chromoplate. The chromatoplate was then developedin a tank 
containing a solvent mixture of chloroform:methanol:28% ammonium hydroxide (80:20:2) to 
separate polar lipids including N-acylphosphatidylethanolamide (NAPE) 31. Sample components 
move upwards through capillary action at different rates, resulting in resolution based on polarity. 
Samples are visualized under UV light or by reaction with iodine vapors, allowing for easy detection 
of known standards that are run in separate columns on the same plate. Authentic standards (50 g 
each) utilized included PC, PE, palmitate, PEA, TAG, and NPPE. Radiolabelled lipid samples were 
overlaid with NPPE (25 g each) to facilitate visualizationwhen incubated with iodine crystals prior 
to scraping and quantification by scintillation counting.  
 
7.3 Results 
7.3.1Total Hrasls-1 mRNA isInducedin BV2 Cells Treated with LPS 
Activation of BV2 microglial cells with LPS can activate pro- and anti-inflammatory 
mediators136. NAEs are acute anti-inflammatory signalling lipids derived from NAPEs that are 
regulated by HRASLS family members. Effects of inflammation activation on HRASLS family member 
expression has not, however, been reported. Both HRASLS-5 and HRASLS-3 are present in the 
genome of murine species, while HRASLS-2 and HRASLS-4 are not. We analyzed the mRNA 
expression of Hrasls-5 and Hrasls-3 throughqPCR analysis of cDNA of BV2 cells that had either been 
treated with control media or media containing LPS. The mRNA expression of total Hrasls-1 was 
also analyzed under these conditions, by performing qPCR with primers specific for the Hrasls-1 
coding region that would recognize both transcript variants.  
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Our results indicated a significant increase in Hrasls-1 mRNA expression upon activation 
with LPS. In this experiment, Hrasls-1 expression was increased 11-fold when cells were activated 
with LPS (Figure 22). Showing a similar pattern, the expression of Hrasls-3 was significantly 
induced 15-fold upon LPS activation. Hrasls-1 levels were below the level of detection in either 
control or LPS-treated cells, suggesting that levels of this N-acyltransferase are insignificant in this 
cell type.  
Comparison of Hrasls-3 and Hrasls-1 levels in control cells illustrates a greater baseline level 
of expression of Hrasls-1 in BV2 cells. There was a significant difference of 8-fold between Hrasls-1 
and Hrasls-3 mRNA within the control treated BV2 cells. Once activated with LPS this difference was 
largely maintained, showing a difference of approximately 6-fold. In both conditions, Hrasls-1 
expression was highest. 
 
7.3.2 The Hrasls-1 0.8 kb transcript, but not the 2.9 kb transcript, is significantly induced by 
LPS-activation of cells 
In order to determine whether a change in one or both transcripts was responsible for the 
induction of total Hrasls-1 observed in LPS-treated cells, we measured the expression by qPCR of 
both transcript variants in BV2 microglial cells that were treated with either 1 g/mL of LPS or 
control medium. We normalized our values to those of the control gene 18S, and then expressed 
these values relative to expression of the Hrasls-1 2.9 kb transcript variant from cells incubated in 
control media. Our results show that activation of BV2 cells with LPS caused a significant induction 
of the expression of the Hrasls-1 0.8 kb transcript variant (Figure 23). We observed a 38-fold 
increase in the expression of the Hrasls-1 0.8 kb transcript variant when comparing cells treated 
with control media, to those activated with LPS. The longer, 2.9kb transcript variant showed no 
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significant change in expression between control or LPS activation, indicating no change in the 
expression of this transcript when BV2 cells are stimulated by a pro-inflammatory molecule.  
When comparing the 0.8 kb transcript variant to the 2.9 kb transcript variant, we observed 
much lower expression of the 2.9 kb transcript variants in both groups (control treated and LPS 
treated). This indicates greater baseline levels of the Hrasls-1 0.8kb transcript in BV2 microglial 
cells.    
 
7.3.3 NAPE content is increased in BV2 cells treated with LPS  
The band corresponding to NAPE was detected and was scraped for quantification by liquid 
scintillation counting. Relative radioactive counts (cpm) were normalized to cell numbers (Figure 
24), so that NAPE levels could be expressed relative to control-treated plates.  Results indicated that 
acute activation of BV2 microglial cells with LPS resulted in a significant 2-fold increase in 
[14C]NAPE content compared to control cells (P< 0.05) (Figure 25). 
 
7.4 Discussion  
 
With respect to HRASLS-1, there is a predominant preference by this enzyme for N-acylation 
using fatty acids transferred from the sn-1 position of glycerophospholipids18. In general, the fatty 
acids located at the sn-1 position are saturated, and are primarily the saturated species palmitate 
and stearate that would generate NPPE/PEA and NSPE/SEA through the Hrasls-1/PLD pathway. 
PEA and SEA are among the major NAE species in animal tissue9,76 and, in injured tissues, high 
levels of saturated , such as SEA and PEA, rather than unsaturated, AEA, NAEs tend to accumulate67. 
The C16:0 NAE, PEA is able to directly activate PPAR- and employ an anti-inflammatory role, by 
altering the transcription of proinflammatory transcription factors, NF-κB and AP-1 58.In addition to 
PEA, C18:0 NAE, SEA is also an important regulator of the inflammatory response. In inflamed or 
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damaged tissues, SEA has proved to be a signaling lipid capable of down-regulating inflammation, 
mediated by the activation of the TRPV1 receptor 67.  Instead of acting directly, SEA utilizes a 
mechanism similar to the “entourage effect”, where it increases AEA concentrations, allowing AEA 
to gate TRPV1 receptors, favoring their desensitization and dampening inflammation 67. It therefore 
seems plausible to hypothesize that during an inflammatory response, Hrasls-1 expression and 
activity may increase due to its catalytic role in synthesizing PEA and SEA, which are both anti-
inflammatory mediators (Appendix B, (C.)).  
 In order to test this hypothesis, we compared the NAPE content formed in cells undergoing 
an inflammatory response versus those that did not.  BV2 microglial cells were treated with the 
TLR4 agonist LPS in order to illicit a pro-inflammatory response. Our results indicate a significant 
increase in NAPE content, within LPS-treated cells. Alongside this experiment, we determined the 
change in mRNA expression of Hrasls-1, Hrasls-3 and Hrasls-5 family members during an acute 
inflammatory response. All three are conserved throughout human, mouse and rat species, and all 
exhibit N-acyltransferase activity in vitro19. Results indicated a significant increase in the expression 
of Hrasls-3 and total Hrasls-1. For Hrasls-1, we first used primers directed towards the coding 
region, which therefore represented the sum of both transcript variants. Hrasls-1 was up-regulated 
to a greater extent than Hrasls-3 upon LPS activation. However, HRASLS-3 is only reported to show 
N-acyltransferase activity in vitro, not in vivo20. Thus, its contribution to the synthesis of NAE in 
cells is likely negligible. Similar to HRASLS-1, HRASLS-5 shows in vivo N-acyltransferase activity 
which results in NAPE generation, and eventual downstream NAE synthesis19. However, Hrasls-5 
expression was undetectable in either group, and is therefore also unlikely to play a significant role 
in NAPE synthesis in BV2 cells, either at rest or during inflammation. Hrasls-1 therefore appears to 
be the predominant mediator of iNAT-regulated NAPE synthesis in this cell line.  
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Although, these results suggest that NAE levels would also be up-regulated under the same 
conditions, it is difficult to make any conclusive statements from our study, however, since the 
parameters of the experiment were not ideal. BV2 microglial cells were treated simultaneously with 
[14C]palmitate and LPS, which may increase the uptake and incorporation of fatty acids into all 
complex lipids through a general mechanism such as increased expression of fatty acid transport 
proteins. In agreement with this possibility, the radioactivity incorporated into NEFA, PC, and 
PE,was also increased in the LPS treated BV2 cells (Appendix A). It is therefore difficult to conclude 
whether increased NAPE was a result of the elevation in HRASLS-1 expression that we found, or an 
increase in the production and availability of the substrates for NAPE synthesis (namely PC and PE), 
or both. In order to determine this, it is critical that this experiment is repeated, but with 
radiolabeling of both plates prior to activation with LPS, so that uptake and incorporation of 
[14C]palmitate into complex lipids is initially identical. Although it would still be possible that 
differences in PC and PE synthesis would occur after addition of LPS, and therefore affect NAPE 
formed, it would remove confounding from differences in rates of fatty acid transport into cells that 
might be affected by LPS treatment. Although radiolabeling experiments provide a rapid means of 
determining whether treatment effects exist, this work would also benefit from other 
methodological studies such as mass spectrometry (MS) analysis of NAPE content in order to 
determine both the quantity and identity of the specific fatty acyl species attached. Finally, in vitro 
assay of cellular lysates, measuring the incorporation of radiolabeled fatty acid from the sn-1 
position of PC into PE23 or, more specifically, into NAE following PLD-mediated hydrolysis of PE, 
would also provide direct evidence of increased cellular N-acyltransferase activity with LPS 
treatment. 
When taken together, these results suggest that up-regulated Hrasls-1 expression plays a role 
in the increased LPS-induced synthesis of NAPE that would support an enhanced production of anti-
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inflammatory saturated-type NAEs67. Clearly, however, mechanistic studies examining the direct 
role of HRASLS-1 in inflammation will be required to confirm this notion but, nevertheless, this 
suggests HRASLS-1 may have important health implications.  
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Figure 22. mRNA content of Hrasls-1, Hrasls-3, and Hrasls-5 in BV2 microglial immunocytes treated 
with control medium or LPS. Data are expressed relative to the mRNA expression of HRASLS-1 
2.9kB control group. Normalized to housekeeping gene, -actin. Significant expression differences 
are denoted by * p<0.05. 
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Figure 23. mRNA content of Hrasls-1 transcript variants in BV2 microglial immunocytes treated 
with control medium or medium containing LPS. Data are expressed relative to the mRNA 
expression of the Hrasls-1 2.9kB transcript variant control group and have been normalized to the 
housekeeping gene -actin. Significant expression differences are denoted by *P<0.05. 2.9 kb: 
Hrasls-1 2.9 kb transcript variant, 0.8 kb Hrasls-1 0.8 kb transcript variant. 
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Figure 24. Image ofBV2 microglial cells on hemacytometer. Replicate plates were treated with non-
radioactive control media or non-radioactive media containing LPS in parallel with radiolabeled 
cells in order to estimate the number of cells per plate after 18 h of treatment. 
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Figure 25.[ 14C]N-acylphosphatidylethanolamide content in BV2 microglial cells treated with 
control medium or medium containing LPS. Quantification was performed by liquid scintillation 
counting and is expressed in cpm normalized per 106 cells analyzed (n=4), *P<0.05. 
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Chapter 8 
Analysis of Hrasls-1 Transcript Variant Expression During Mid- to Late-Stage Embryogenesis  
8.1 Introduction  
Embryogenesis is the process by which the embryo forms and develops into a multicellular 
organism from a single cell.  Due to its rapid (21 days) gestational period, the mouse is frequently 
used as an embryological model101. The intricate processes that result in formation of the tissues 
and organs “require the activation and inactivation of specific genes at specific times, highly 
integrated cell-cell interactions, and interactions between cells and their non-cellular 
environment”137.  
NAEs have been shown to be constituents of human amniotic fluid 101. Previous studies also 
suggest roles for NAE receptors in placental physiology, embryogenesis, and fetal development, and 
increasing evidence suggests that NAE signaling is critical to early pregnancy events101. In the 
present work, studies report the expression of HRASLS-1 expression in mouse embryos at varying 
developmental time points.  
 
8.2Methods 
8.2.1 Harvest of Mouse Embryos 
For harvest of embryos (AUP 12-09), timed mated mice were plug checked by animal health 
technicians to determine embryonic day 0.5, then pregnant dams were euthanized 10, 14, and 18 
days later. Embryos were harvested and snap frozen in liquid nitrogen, then stored at -80C until 
RNA isolation. 
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8.3 Results  
8.3.1Hrasls-1 transcript variants are regulated during embryogenesis. 
We analyzed the expression of both Hrasls-1 0.8kb and 2.9kb transcript variants during mid- 
to late-stage embryonic development by homogenizing whole mouse embryos at time points E10.5, 
E14.5 and E18.5.  RNA from embryos was extracted and reverse transcribed to cDNA for 
quantitative analysis. Expression levels were analyzed by the CT method, with transcript levels 
normalized to 18S loading control, and then compared to the 0.8 kb transcript variant at embryonic 
development day 14.5 (Figure 26).   
 The Hrasls-1 0.8 kb transcript variant showed stable expression throughout development. 
We saw no significant difference in levels of expression between day 10.5, 14.5 or 18.5. However, 
expression of the Hrasls-1 2.9 kb transcript variant was variable between all three time points.  The 
2.9 kb transcript showed an approximate 40-fold decrease in expression from embryonic 
development day 10.5 to day 14.5. Even more pronounced was the amplification seen from 
embryonic day 14.5 to day 18.5. Over the course of 4 days, during the last two time points measured 
(embryonic day 14.5 to 18.5), the Hrasls-1 2.9kb transcript showed a 2000-fold increase.  These 
results suggest a varied role for each HRASLS-1 transcript variant in embryonic development, since 
one shows a significantly greater degree of regulation than the other.  
 When comparing the two transcript variants during embryonic development, results indicate 
higher expression of the 2.9 kb transcript than the 0.8 kb transcript at both day 10.5 and 18.5. At 
embryonic development day 14.5, both transcript variants show relatively low expression. As a 
result, we see no significant different in expression levels between the two transcripts at this time 
point.   
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8.4 Discussion  
Enzymes involved in brain signaling become stimulated as early as embryogenesis. 
Furthermore, lipid-signaling molecules such as AEA, OEA, and PEA have been shown to be elements 
of human amniotic fluid 101, although their biological role within these fluids is still unknown. 
Previous studies also focus on the expression and role of cannabinoid receptors in placental 
physiology, embryogenesis, and fetal development101. It is known that a tonic physiological level of 
anandamide is essential for properpreimplantationto occur in mice, where either too much or too 
little can delaydevelopment138. Whether other NAEs have any effects during pregnancy or 
embryogenesis remains unknown.  Due to its role in synthesizing NAE-precursor NAPEs, we chose 
to investigate the expression of both mRNA transcript variants of HRASLS1 at embryonic 
development day 10.5, 14.5 and 18.5. Results indicate that the 0.8 kb transcript variant remained 
largely unchanged throughout these developmental time points, while the 2.9 kb transcript variant 
underwent a profound, two thousand-fold induction in the days immediately prior to parturition. 
This massive induction of Hrasls-1 strongly suggests a role in embryonic development that merits 
further study. It is important to note that the first time point analyzed (E10.5) commences the 
second half of embryonic development. In order to achieve a better understanding of the regulation 
of Hrasls-1 during embryonic development, it would be useful to analyze embryos at an early stage, 
particularly during the first week of development when organogenesis is occurring.   
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Figure 26. mRNA content of Hrasls-1 transcript variants at different stages of embryonic 
development. Data are given relative to the mRNA expression of the Hrasls-1 0.8 kb  transcript 
variant at embryonic development day 14.5 (n = 3 for all groups) and have been normalized to the 
housekeeping gene 18S. 
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Chapter 9 
An Integrated Discussion  
While each study presented was unique, and directed at specific objectives, the results 
obtained may be discussed cohesively in order to address future directions within this field.  
When analyzing the metabolic data, a result that was consistent throughout the tissues 
measured was the relative level of expression between each transcript variant in each measured 
state. We found that, in general, a higher level of the 0.8 kb transcript variant was present in all 
states and tissues, in comparison to the 2.9 kb transcript variant. What this initially indicates is that 
modulation of the Hrasls-1 0.8 kb transcript variant may be primarily responsible for the up-
regulation of overall Hrasls-1 expression with fasting in most tissues, except heart and brain.   
Observation of these results, with the results of variable transcript variant stability, can 
implicate both findings and permit for further discussion. In the previous chapter, it was proposed 
that due to various confounding factors, the 2.9 kb transcript variants was not less stable, and 
alternatively the 0.8 kb transcript variant showed quicker mRNA degradation. This imposes 
questioning as to what is truly happening upon increased activation of the 0.8kb transcript variant 
within the fasted state. The 0.8 kb transcript variant may not be as stable, suggesting that its 
increased activation may be short-lived and sufficient in mediating the necessary response for a 
short-term substrate depletion, but unable to maintain high mRNA expression as the fast persists.  
Nevertheless, the 2.9 kb transcript variant is also up-regulated during the fasted state, and due to its 
observably slower degradation, may be responsible in maintaining substrate oxidation via fatty acid 
metabolism. Interestingly, within study #3, the 0.8 kb transcript variant was alone at showing 
significant mRNA expression induction upon activation with LPS.  
Due to the coinciding increase in NAPE content, it is suggested that HRASLS-1 may play a role 
in regulating NAPES, although the durability of this effect is unknown, as the 0.8 kb transcript 
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variant mRNA may be degraded shortly after. Furthermore, during embryogenesis, only the 2.9 kb 
transcript variant showed a significant change in mRNA expression. Therefore, future work would 
largely benefit from integrating the potential transcript stability of both transcript variants under 
each physiological demand investigated, as this would give further insight to the significance in 
activating either transcript variant for either a restricted or resilient response.  
 As presented within the discussion of HRASLS-1 in substrate oxidation and inflammatory 
regulation, there is evidence to suggest that future work should look at the role of HRASLS-1 in 
obese models that exhibit both high levels of circulating fatty acids as well as an overactive 
inflammatory response.  Control of inflammation represents an essential approach in the clinical 
management wide range of diseases. For example, obesity is described as a “chronic, systemic low-
grade state of inflammation” 139. Furthermore, macrophages, which play a critical role during 
inflammation, are increased in adipose tissue of obese139. It is possible that HRASLS-1 may 
function to increase fatty acid oxidation and decrease adipogenesis, thereby decreasing adiposity 
and offering hope for treatment of obesity. It is also possible that HRASLS-1 may mediate further 
protective effects in obesity, by attenuation of inflammation. A study looking at the possible 
beneficial roles of HRASLS-1 in obese mice would be highly valuable in elucidating a physiological 
role for this enzyme.  Data, showing that HRASLS-1 is activated during an inflammatory response to 
potentially increase the release of anti-inflammatory lipid mediators, raises the possibility that 
pharmacological treatments that increase activation of this enzyme might be of promising 
therapeutic benefit, especially for obese individuals. 
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Chapter 10 
Conclusion  
There are significant changes in the mRNA expression of HRASLS-1 during different 
nutritional states in diverse tissues. This is important since very little is known about the 
physiological role of HRASLS-1. Due to the lack of substrate specificity shown by HRASLS-1, it is 
difficult to suggest one specific role for the enzyme. Indication of tissue specific activation of fat 
metabolism-associated genes, positively associated with the up-regulation of HRASLS-1, give further 
insight on the possible mechanism of action. The data we have generated on the differential 
expression of this enzyme provides a starting point from which we can infer a unique role within 
each tissue. In order to truly elucidate the physiological relevance of HRASLS-1, further work clearly 
must be done. Protein expression analysis via Western blotting would be useful for further 
characterization of HRASLS-1 expression, but unfortunately an acceptable antibody that recognizes 
the murine isoform has not been available during my studies.  
From my thesis work it is evident that these transcript variants are differentially regulated. 
Although we predicted that the 2.9kb transcript variant would show greater instability due its 3’ 
UTR AU-rich elements108, results indicated the opposite. Further work must be done in order to 
understand the different mechanisms that regulate the two transcript variants, and to make concise 
implications about the transcript variants in varying physiological conditions.  
 My thesis work suggests a potential role for HRASLS-1 in the regulation of NAPE during an 
acute inflammatory response, since a coinciding increase between Hrasls-1 mRNA expression and 
NAPE content was seen. Hreals-1 showed a significantly greater induction than both Hrasls-3 and 
Hrasls-5 under an acute activation by LPS and may play a predominant role in NAPE synthesis 
during the inflammatory response in BV2 cells, although gene knockdown studies would be 
required to confirm this. A role for HRASLS-1 in neuroinflammation has clinical implications for the 
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treatment of disease, although the significance of HRASLS-1, as well as HRASLS-2 and HRASLS-4 
within the human system must first be understood.   
To date, very little is known about the role of NAE’s during embryogenesis. AEA has been 
identified during early stage implantation in the embryo82, although the role of additional NAEs on 
early pregnancy and embryogenesis remains unknown. These results illustrate that there are 
significant changes in the mRNA expression of Hrasls-1 during embryonic development, suggesting 
a unique role for NAEs that act as downstream products of the HRASLS-1 pathway. Further 
investigation of this role seems likely to yield important information on the nature of lipid-mediated 
signalling in development, with implications for both fetal and maternal health, and reproductive 
success. 
In conclusion, this work presents an initial insight into the physiological role(s) of HRASLS-1, 
and suggests that HRASLS-1 may be valuable in multiple physiological processes ranging from 
substrate oxidation regulation to embryonic development to inflammation.  
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Appendix A: Supplementary figures of TLC- resolved lipids. 
A     B
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Suppl Fig. 1. [ 14C]PC (A), [ 14C]PE (B), and [ 14C]NEFA (C) content in BV2 microglial cells treated with control medium or 
medium containing LPS for 18 h.  Quantification was performed by liquid scintillation counting and is expressed in cpm 
normalized per 106 cells analyzed (n=4), *P<0.05. 
 
Control LPS
0
100000
200000
300000
***
[1
4
C
] P
E
 c
o
n
te
n
t
(c
p
m
/1
0
6
 c
e
lls
Control LPS
0
100
200
300
400
500 ***
[1
4
C
]F
F
A
 c
o
n
te
n
t
(c
p
m
/1
0
6
 c
e
lls
)
Control LPS
0
200000
400000
600000
***
[1
4
C
]P
C
 c
o
n
te
n
t
(c
p
m
/1
0
6
 c
e
lls
)
 106 
 
Appendix B: Illustrations of proposed physiological roles of HRASLS-1 
 
A.             B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proposed HRASLS-1 mediated pathway within the fasted state of white adipose tissue (WAT), liver, and kidney. Due to the 
continued requirement for energy by peripheral tissues during the fasted state, HRASLS-1 of WAT mediatessignalling of 
lipolysis activation and leads to a release of NEFA into the circulation (A). HRASLS-1 of peripheral tissues synthesizes NAE-
precursors in order to signal to increase the uptake of NEFA via FAT/CD36, and the utilization of NEFA in  -oxidation, 
generating a switch to the use of NEFA as the primary substrate for energy metabolism (B).  
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  C. 
 
 
 
 
 
 
 
 
 
 
 
 
Proposed HRASLS-1 mediated pathway during an LPS-induced inflammatory response. HRASLS-1 synthesizes precursor NAE 
molecules that will induce PPAR- activation and, in turn, inhibit transcription of specific pro-inflammatory genes. The NAEs, 
PEA and SEA, are also able to inhibit the degradation of AEA (through FAAH), which can elicit an anti-inflammatory response 
independently, and well as desensitise TRPV1 receptors to pro-inflammatory stimuli (C).  
